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Abstract
Gene Modification with Triplex-Forming Oligonucleotides
Jennifer M. Kalish
2006
Triplex-forming oligonucleotides (TFOs) bind DNA in a sequence-specific
manner and mediate targeted genome modification. Triplexes bind parallel to the purine
strand of the duplex in the pyrimidine m otif and anti-parallel in the purine motif. TFOs
in both motifs have been shown to direct psoralen adduct formation in cells, leading to
mutagenesis or recombination. Only purine m otif TFOs have been shown to mediate
genome modification without using a DNA-adduct. In this work, we report the ability o f
a series o f chemically modified pyrimidine m otif TFOs to induce repair and
recombination in the absence o f any DNA-reactive conjugate. We find that a number of
modified TFOs show increased formation o f non-covalent triplexes under physiological
conditions. However, only the N3'->P5' phosphoramidate and 5-(l-propynyl)-2'deoxyuridine-modified TFOs mediate induced recombination in cells and stimulate repair
in cell-free extracts. Additionally, we establish the ability o f TFOs to induce gene
correction at a single-copy chromosomal locus in mammalian cells at frequencies up to
0.1%. We demonstrate sequence, target site, and dose-dependent effects. Finally, we
develop an assay to detect incisions made in repair o f a triplex. This work expands the
number o f targets available for triplex-mediated gene targeting, shows effective targeting
at a chromosomal locus, and takes first steps towards understanding the mechanism of
triplex-induced gene correction.
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Appendix 1
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Appendix 2

I

Nucleotide excision repair pathway. The parallel pathways o f global genome repair
(GGR) and transcription-coupled repair (TC-NER) recognize helically distorting lesions
in DNA and polymerase blocking lesions in transcribed regions o f DNA, respectively. In
GGR, XPC-hHR23B recognizes helical distortions and in TC-NER lesions are
recognized by blockage of RNA polymerase II. In GGR, TFIIH and possibly XPG are
attracted to XPC-hHR23B bound to the lesion. TFIIH creates an open complex via XPB
and XPD, leading to the recruitment o f XPA and RPA, and to the common incision
pathway. In TC-NER, CSA, CSB, TFIIH, XPG, and possibly other factors, replace RNA
polymerase II, leading to the recruitment o f XPA and RPA, and to the common incision
pathway. The incision pathway consists o f XPG making the 3' incision and ERCC1-XPF
making the 5' incision. After the dual incision is completed, gap-filling DNA synthesis
occurs followed by ligation. This is an adaptation o f a figure from de Laat, W.L., et al.,
(1999). Genes and Development 13: p. 768-785.
xii
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J. M. Kalish
Triple helix (triplex) formation was first described in 1957 by Felsenfeld and
colleagues, who while studying polypurine/polypyrimidine duplex interactions, noted the
binding o f a second polypyrimidine strand to the duplex [1], Triplex-forming
oligonucleotide (TFO) binding occurs under physiologic conditions and in a sequence
specific manner [2-5]. The target specific binding o f TFOs has been used to deliver DNA
interacting molecules to a specific genetic location. While binding to the double helix,
TFOs alter the helix and induce cellular repair mechanisms. These repair mechanisms
lead to TFO alteration of gene metabolism via transcription repression, inhibition of
DNA replication, and induction o f site-specific mutagenesis and recombination [6-11].
Thereby, TFOs have the potential to introduce permanent changes in genomic DNA in a
variety of contexts.

Triplex Chemistry and Binding Code
TFOs bind DNA in the major groove of DNA in a sequence-specific manner to
homopurine sequences in two distinct motifs [2-4, 12]. Triplex formation is favored at
polypurine/polypyrimidine regions o f DNA and can occur with the third strand oriented
either parallel or anti-parallel to the purine strand o f the duplex. TFOs bind to duplex
DNA using an alternative set of hydrogen bonds called Hoogsteen bonds [1], Purine
motif TFOs bind anti-parallel to the duplex via reverse-Hoogsteen hydrogen bonds and
pyrimidine m otif TFOs bind parallel via Hoogsteen bonds [2-4, 12]. In the anti-parallel,
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purine motif, the triplets are G.G:C and A.A:T; whereas in the parallel, pyrimidine motif,
the canonical triplets are C+.G:C and T.A:T (Fig. 1). In the pyrimidine motif, protonation
o f the cytidine is required for triplex formation [3, 13, 14].

Chemical Modifications
To enhance the biological activity o f TFOs there has been a focus on chemical
modifications (Appendix 1). Under physiologic conditions, potassium levels are high,
magnesium levels are low, and pH is neutral. High potassium promotes G-quartet
formation, which inhibits the activity o f G-rich purine m otif TFOs [15-17], Magnesium
supports third-strand binding by charge neutralization. Neutral pH disfavors cytosine
protonation, which is needed for triplex formation in the pyrimidine motif, unless the
cytidines are modified [3, 13, 14]. As a result, a variety o f chemical modifications have
been explored to offset the effects o f these factors on TFO binding and thereby increase
binding affinity and enhance potential biological activity o f the TFOs. These
modifications include sugar, backbone, and base modifications.
Purine M otif Modifications
Chemical modifications such as N, N-diethylethylenediamine (DEED) have been
used to enhance binding and thereby the biological activity o f TFOs in the purine m otif
[18-22], The G-rich nature o f purine m otif TFOs allows them to form G-quartets under
physiological conditions which include high levels of potassium [15-17],

1.3
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7-deazaxanthine and 6-thioguanine substitutions have been used to offset the diminished
TFO binding in the presence of high levels o f potassium (due to the formation o f Gquartets), and such molecules have shown increased effectiveness in cells [23-25].
Pyrimidine M otif Modifications
For triplex formation in the pyrimidine motif, an acidic pH is needed for N3
protonation o f cytidines (C) [14]. Therefore, TFOs with several adjacent C ’s require a
lower pH for binding to duplex DNA than TFOs with dispersed C’s [14, 26]. TFOs with
5-methyl-2'-deoxycytidine (5meC) [27-29] and 5-(l-propynyl)-2’-deoxyuridine (pdU)
[29] substitutions were shown to alleviate the need for an acidic pH and to improve the
effectiveness of mutagenesis targeted by TFO-conjugated delivery o f 4'-hydroxymethyl4, 5', 8-trimethylpsoralen (psoralen) to specific sites. Other demonstrated base
substitutions for cytidine include: pyrrolidino pseudoisocytidine [30], 8-oxoadenine [31,
32], N7-2'-deoxyguanosine [33], 7,8-dihydro-8-oxoadenine [34], 8-oxo-2'deoxyadenosine [35, 36], 2-aminopyridine [37], and 8-aminoguanine [38]. TFOs
containing these modified bases have enhanced binding affinity at neutral pH compared
to unmodified TFOs [30-38].
Sugar substitutions such as 2'-0-am inoethyl (2'-AE) [39, 40] and 2'-0-m ethoxy
(2'-OMe) [41, 42] enhance TFO stability and affinity for binding duplex DNA. Work by
Michael Seidman’s group showed that 2'-0-aminoethyl and 2'-0-m ethoxy substitutions
on psoralen-conjugated TFOs in the pyrimidine m otif enhance gene knock-out in
mammalian cells [40], More recent work from this group demonstrated that only a
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minimal number o f 2'-0-aminoethyl substitutions clustered together was sufficient for
enhanced gene knock-out activity [43, 44],
Backbone modifications have also been extensively used to augment TFO binding
affinity and intracellular activity through reduction o f charge interactions [45],
Replacement o f the bridging N3 oxygen with a nitrogen improved TFO binding in vitro
[46] and when conjugated to psoralen these TFOs were used to target integrated J I1V-1
pro virus within cell nuclei [47]. The TFO binding and psoralen delivery to chronically
infected cells containing the HIV-1 pro virus was demonstrated using a restriction
protection assay, where DNA digestion was prevented when the psoralen adduct was
present at the correct target site[47]. Replacement o f a non-bridging oxygen with amino
groups such as N, N-diethylethylenediamine (DEED), or N, N-dimethylaminopropylphosphoramidate (DMAP) as chemical modifications on the third strand have been
used to enhance triplex formation under physiologic conditions [48]. Morpholinomodified TFOs have both a sugar and a backbone modification and can also form stable
triplexes [49].
Peptide Nucleic Acids
The peptide nucleic acid (PNA) resembles DNA, with purine and pyrimidine
bases being attached to a polyamide backbone. PNAs can be used to mediate gene
modification and bind to DNA in several different ways (Fig. 2). PNAs can bind through
strand invasion to one or both o f the strands o f the duplex [50, 51]. This binding is via
Watson-Crick base pairing between the PNA and the DNA duplex and disrupts the DNA
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duplex binding to itself [52], PNAs can also form triplexes with a strand invading PNA
conjugated to a flexible linker molecule with an additional sequence that can form
Hoogsteen bonds with the PNA-DNA duplex [52], This PNA clamp binds to a single
strand o f duplex DNA via both Watson-Crick base pairing and Hoogsteen base pairing
[52]. PNAs have a greater binding affinity as third strands than unmodified TFOs of the
same sequence [53], Mixed sequence (purine and pyrimidine) PNAs have been
developed, which are an advantage over TFOs that only bind to AG-rich or TC-rich
stretches o f DNA [54], The PNA clamp was demonstrated to induce XPA-dependent
DNA repair and recombination [52], In order to expand the number of target sequences
for PNA binding, tail-clamp PNAs which have an additional mixed (purine and
pyrimidine) sequence as part o f the strand invasion sequence have been developed and
were shown to inhibit transcription [55, 56].

TFO-Targeted Gene Modification
TFOs as a tool fo r delivery o f DNA reactive agents
TFOs have been used to deliver DNA reactive molecules to specific locations on
the DNA (Fig. 3A). In this regard, TFOs represent a means o f effective gene
modification. The DNA-reactive agents include psoralen [57, 58], camptothecin (CPT)
[59, 60], padlock TFOs [61-63], [5-(125)I]dCMP [64, 65], and acridine [66, 67], Based
on the potential for molecular recognition of unique genomic sites, Havre et al. used a
TFO to deliver psoralen in a sequence-specific manner [57, 58]. TFO delivery of
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psoralen followed by photo-activation o f the psoralen, induced site-specific mutagenesis
in viral DNA within mammalian cells [57, 58], Activation of gene expression has been
demonstrated by pso-TFOs in a manner dependent on photo-crosslinking [68].
Topoisomerase I is a DNA-relaxation enzyme that is an important therapeutic
target for CPTs in cancer chemotherapy. Camptothecins as agents alone do not bind to
specific DNA regions, leading to drug side effects induced by the non-specific binding.
CPT conjugation to a DNA targeting agent such as a TFO shows promise o f increasing
the specificity o f drug delivery. Binding o f these CPT-TFO conjugates to duplex DNA
has been demonstrated in vitro and their cellular activity has been demonstrated [59, 60].
Padlock TFOs are TFOs with extra sequences (complementary to each other) on
either side o f the polypurine/polypyrimidine TFO binding sequence, the ends o f which
are ligated together with T4 ligase after TFO binding [62], This end-ligation forms a
loop around the plasmid DNA containing the TFO binding site (TBS) [62] and has been
used to conjugate targeting peptides to plasmids [61] and to inhibit transcription
elongation [63], TFOs are also used to deliver [5-(125)I]dCMP which, after decay
accumulation, causes double strand breaks in the targeted DNA [64, 65],
Binding Affinity Correlates with Intracellular Activity
Wang et al. showed that psoralen-conjugated TFOs transfected into monkey COS7 cells can induce base pair-specific mutations within the supF reporter gene in a simian
virus 40 (SY40) genome in cells, at a frequency in the range o f l% -2% [11], The key
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finding in this seminal work was that the binding affinity o f the TFO to its target site, as
measured in vitro, was highly correlated with its intracellular activity. TFOs with Kd's
(equilibrium dissociation constants) in the range o f lx l0 ‘9 M were active; those with Kd’s
o f lxlO"6 M were not. A more specific threshold has been determined for induced DNA
recombination and repair, where a binding affinity greater than

1 x 1 0 ‘7 M

is necessary for

induced recombination in cells and induced repair in cell-free extracts [18]. Binding
affinity in vitro is influenced by Mg2+ and K+ concentrations and pH while in vivo
chromatin structure and transcriptional activity are also important factors. Transcription
through the target region substantially enhances TFO chromosomal targeting, suggesting
that gene modification with TFOs may be more effective at chromosomal loci that are
highly expressed [69],
The binding affinity o f a TFO in the anti-parallel, purine m otif is not only
influenced by the number of mismatches at the binding site but is also influenced by TFO
length. TFOs of length 30, 20, and 10 designed to bind to all or a portion o f a 30 base
pair polypurine site have K fs o f 2x1 O'8 M, 3x1 O'7 M and SxlO’3 M, respectively [70],
Correspondingly, the amount o f induced repair in HeLa cell-free extracts decreased with
TFO length (the 30-mer in the purine m otif demonstrated the greatest induced repair,
while the 20-mer and then the 10-mer showed lesser effects) [70], The pattern of
mutations produced by TFO-targeted psoralen adducts on an episomal target in COS-7
monkey cells is also influenced by the length o f the TFO [71]. Additionally, excision of
TFO-damaged DNA is inhibited by a linked 30-mer TFO (whereby the triplex extension

1.8

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

J. M. Kalish
exceeds the nucleotide excision repair (NER) canonical excision patch) but not by a 1ti
mer TFO [71].
TFO-Inhibition o f Transcription
Transcription has been inhibited by TFOs binding to a variety of promoters and
other targets in and near genes of interest. TFOs were shown to reduce c-myc expression
[6, 72, 73] and to inhibit Tat-dependent in vitro transcription [74], Inhibition of
transcription is dependent on the accessibility o f the TFO binding site (TBS) when the
DNA is bound in the nucleosome [21] and TFOs have been shown to access binding sites
within the chromatin structure [47], TFOs covalently bound to duplex DNA and PNAs
through strand invasion inhibit replication o f plasmid DNA in vivo [75]. Chemically
modified TFOs were also used to inhibit transcription. 2'-0-methyl-modified TFOs
binding to DNA block recognition of duplex DNA by a eukaryotic transcription factor
[76] and LNA-modifled TFOs inhibit transcription in vitro [77], Phosphoramidate
modified-TFOs have been shown to inhibit transcription o f several HIV genes [78-80],
Dual conjugation to phenylacetate mustard enhanced inhibition o f Her2 gene expression
[81]. Psoralen-conjugated TFOs were used to inhibit a gene involved in cutaneous
imflammation [82], the human rhodopsin gene [83], and Ets2 transcription in prostate
cancer cells [84], These successful inhibitions suggest that TFOs may be useful as agents
to treat skin diseases, ocular defects, and prostate cancer.
PNAs have been shown to arrest transcription elongation by invading double
stranded DNA and forming a stable (PNA)2/DNA complex [85]. Conjugation o f a PNA
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to a peptide containing eight lysines increased the inhibition of transcription [86] and
lactose-modified PNAs had increased cellular update and inhibition o f transcription [87],
PNA triplexes presented a stable barrier to DNA polymerase extension [88]. Tail-clamp
PNAs have been shown to bind duplex DNA and inhibit transcription [55]. PNAs have
also been used to deliver peptides to act as transcription activators [89].
TFO-Directed Mutagenesis
Knock-out o f chromosomal genes mediated by psoralen-TFOs has been
demonstrated. In one study, the supF reporter gene integrated into the chromosome o f
mouse fibroblasts was used as a target [90], Again, only high-affinity TFOs were active,
achieving targeted mutagenesis frequencies o f 0.1%. In the supF experiments, essentially
unmodified G-rich oligonucleotides (except for 3'-end-capping) designed to bind in the
anti-parallel m otif were used. A set o f experiments to target the hprt gene in hamster
CHO cells, in contrast, used a series o f T-rich psoralen TFOs (because the A-rich target
favored the parallel motif) [42]. In these experiments, the unmodified TFOs were
ineffective. A second conjugation o f the TFO to an intercalator, either acridine or
pyrene, was needed to provide additional binding affinity [42], Such doubly modified
TFOs yielded hprt mutagenesis at frequencies in the range o f 10'3. More recent studies
have demonstrated that pyrimidine TFOs substituted with 2'-aminoethyl sugar residues
are highly active in targeting psoralen adducts and thereby mutations to the hprt gene,
with frequencies in the range o f 0.14% [43]. Psoralen conjugated PNAs were effective in
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inducing mutagenesis as well [91]. TFO-induced mutagenesis was also seen secondary
to double strand breaks with [5-(125)I]dCMP labeled TFOs [64, 65],
However, the mutagenesis induced in the supF and hprt chromosomal targets,
while site-specific in the sense that all the mutations clustered around the third-strand
binding site, was somewhat variable. Hence, these experiments suggested that psoralencoupled TFOs may be useful for gene-specific knock-out but not necessarily for
predictable base pair-specific mutagenesis. As a research tool, however, psoralen TFOs
have served as useful reagents to prove the ability o f oligonucleotides to bind as third
strands to chromosomal sites in living cells. The importance o f these results is to
establish the concept that DNA binding molecules can be used to direct site-specific
genome modification and to show that the cell and nuclear membranes and the packaging
o f the DNA into chromatin are not insurmountable barriers to gene targeting with
antigene oligonucleotides.
TFO-Directed Mutagenesis without Psoralen Conjugation
In the course of the work with psoralen TFOs, Wang et al. observed that
unconjugated TFOs were also capable o f inducing mutations in the target gene, at least
when the binding affinity was sufficiently high (Fig. 3A) [70], TFOs can induce
mutations in a sequence-specific manner in somatic cells in adult mice [10]. Transgenic
mice carrying multiple copies o f lambda vector DNA in their genome were injected
intraperitoneally with a G-rich TFO specific to the target site (Fig. 4) [10]. TFO-induced
mutagenesis was detected in a wide variety o f tissues including skin, liver, kidney, and
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lung [10]. Again, the mutations were generally within the TFO target site. PNAs have
also been used to target the chromosomal supF reporter gene, in mouse cells, yielding
frequencies o f mutagenesis of 0.1% (10-fold above background) [92], PNA-induced
mutagenesis was target specific with the majority o f mutations falling within the PNA
binding site.
TFO-Induced Recombination
Based on the concept that third-strand binding, with or without psoralen coupling,
can trigger DNA repair, Faruqi et al. hypothesized that such binding might also be
recombinogenic due to the production o f repair-dependent DNA strand breaks [8, 9]. To
test this, two distinct recombination assays were used, intramolecular and intermolecular
(Fig. 3B). Using an SV40 vector containing two mutant copies o f the supF gene (Fig.
5A), they found that both psoralen conjugated purine m otif TFOs [8] and TFOs without
psoralen can stimulate intramolecular recombination [9]. This induced recombination in
the case of the TFO without psoralen was found to be dependent on the presence o f
functional XPA protein [9],
These results were extended to a chromosomal target, in which two mutant
thymidine kinase (TK) genes were integrated as direct repeats into a single chromosomal
site in mouse fibroblasts (Fig. 5B) [93]. High-affmity TFOs targeting a region in
between the two TK genes yielded recombination at a frequency o f approximately 10"4,
about 100-fold above background. When the TFOs were micro-injected into the nuclei of
the cells (-2000 copies/cell), the yield o f recombinants increased to l%-2%, 10,000-fold
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over background [94], Analysis of the recombinant clones revealed all the recombination
events involved gene conversion rather than crossover recombination [93],

Repair Pathways and TFO Effects
The TFO mutagenesis effect was shown to be a consequence o f the stimulation of
DNA repair by the formation o f a triple helix, which can be recognized by the nucleotide
excision repair (NER) complex as a "lesion" (Appendix 2). TFO-induced mutagenesis
was not detected in cells deficient in XPA (a key NER recognition protein) but was
restored in cells that were complemented with XPA cDNA[70]. Similarly, triplexinduced mutagenesis was not detected in Cockayne’s syndrome (CS) group B cells (cells
deficient in transcription-coupled repair) but was detected in the cDNA corrected cell line
[70], Thus, both the overall NER pathway and the transcription-coupled repair pathway
play a role in triplex-induced mutagenesis. Gene activation by TFOs was unchanged in
XPA, XPD and XPG deficient cell lines, thus gene activation is dependent on other repair
pathways as well [68].
Intermolecular recombination between plasmid targets and short DNA fragments
can be detected in human cell-free extracts, in a process that is dependent on XPA and
Rad51 [95]. TFO-induced recombination in an episomal target in cells is also dependent
on the NER pathway [9]. The repair and replication complex, replication protein A
(RPA) recognizes triplex structures but also forms nonspecific DNA aggregates at higher
concentrations [96]. In the presence o f RPA, XPA binds to the triplex structure and
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decreases the non-specific binding o f RPA [96]. Therefore, the synergy of RPA and
XPA confers specificity and stringency for triplex lesion binding, and likely represents a
key recognition step in the repair o f triplex structures.

Donor Effects
The observation of the ability o f third-strand binding to provoke DNA repair and
stimulate recombination led to the development o f a strategy to mediate targeted gene
conversion using a TFO linked to a short DNA fragment homologous to the target site
(except for the base pair to be corrected) (Fig. 3B) [97]. In this bi-functional molecule,
the TFO domain mediates site-specific binding to target the donor molecule to the desired
gene [97], This binding also triggers repair to sensitize the target site to recombination
[97]. The tethered homologous donor fragment can participate in recombination and/or
gene conversion with the target gene to correct or alter the nucleotide sequence.
Using a bi-functional oligomer with a 40-mer donor domain and a 30-mer TFO
domain, correction of a single base pair mutation in the supF reporter gene within a SV40
vector in COS-7 cells was achieved [97]. Correction frequencies were in the range o f
0.1% with the full bi-functional molecule [97], Oligonucleotides consisting o f either
domain above or o f either domain substituted with heterologous sequences reduced
activity by 10-fold or more [97]. The donor domain alone consistently did mediate some
gene correction, as would be expected, based on the known ability o f DNA fragments to
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mediate some level o f recombination. However, there was a clear synergism due to
combination with the TFO domain [97].
When measuring induced recombination in HeLa cell-free extracts, tethered and
untethered TFOs and donors showed similar recombination frequencies [95]. This
unlinking allowed for further exploration o f the distance over which TFO binding could
exert an effect on recombination by a short donor DNA molecule. A similar PNA was
coupled with a 40-mer DNA donor molecule and induced recombination was measured in
cell-free extracts [52], Correction o f a mutated reporter gene was found to be over 60fold above background [52] when the PNA and donor were linked but was also
demonstrated without covalent linkage.

Distance and TFO Effects
Given that in vivo there may not always be a TFO target site adjacent to the
desired site o f gene modification, the distance constraints between the TFO binding site
and the mutation site to be corrected by recombination were studied. The episomal target
with the dual supF genes described above had the upstream gene 4 base pairs from the
TFO binding site and the downstream gene 29 base pairs from the site (Fig. 5A) [8], In
the chromosomal TK assay, the TFO binding site was 0.8 kilo bases and 0.7 kilo bases
away from the genes, respectively (Fig. 5B) [94], Recent work demonstrated in two
episomal reporter systems that TFO-induced recombination was detectable at distances
(between the TFO target site and the mutation to be corrected) from 24 base pairs to 750
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base pairs (Fig. 5C) [18], In both systems, recombination between the mutated gene on
the episomal target and a wild-type donor fragment in the presence of TFO was measured

[18]-

TFO Delivery
While the TFOs are active gene targeting molecules, delivery is a key factor in the
biological activity of TFOs. Chromatinization o f the DNA target, intracellular ion
concentrations, and cytoplasmic versus nuclear separation of the TFO and DNA target
are hurdles that have to be overcome in delivery o f a TFO into a cell. TFOs have been
delivered into cells via lipid mediated TFO delivery [9, 98, 99] and electroporation [11,
43], Cells have been directly injected [93] and mice have been intraperitoneally injected
with TFOs [10]. Using cationic lipids as transfection reagents, compared to
microinjection, showed much lower frequencies o f recombination [93]. Cell membrane
permeabilization by digitonin [47, 69] or streptolysin-0 [92] has also been used.
Conjugation o f TFOs and PNAs to a transport peptide derived from antennapedia has
also been explored [100-102], Such conjugation increased mutation targeting frequencies
in a chromosomal reporter gene by 20-fold compared to TFO alone, in a dose responsive
manner [101]. This effect was target specific and not due to the antennapedia peptide
alone [101]. Confocal microscopy demonstrated increased cellular uptake o f the
conjugated TFO [101]. Taken together, these data suggest that TFO conjugation to
antennapedia increases intranuclear delivery o f TFOs.
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Specific Aims
Both purine and pyrimidine TFOs have been used to direct psoralen to a specific
target, but only purine TFOs have been shown to induce genomic changes through repair
and recombination when noncovalently bound to the duplex [9]. Previous work in our
lab has largely focused on the purine motif, showing that purine TFOs are active in repair
and recombination in cell-free extracts, in cell culture, and in mice [8, 10, 71, 92],
Canonical nucleotides do not bind with high affinity in the pyrimidine m otif under
physiological conditions due to the requirement for cytosine protonation in the formation
of Floogsteen bonds [103], In order to make pyrimidine TFOs a more effective tool,
chemical modifications need to be used to enhance triplex stability in vivo. Modifications
such as methylated cytosine, base substitutions, or sugar substitutions improve affinity in
the pyrimidine m otif and have been used for TFO-mediated-delivery o f DNA
intercalators [29, 43],
In Chapter 2, a series o f chemical modifications was examined for their ability to
induce recombination and repair in the pyrimidine motif. The most effective o f these
modifications were the N3'->P5' bridging phosphoramidate (amidate) modification and
the 5-(l-propynyl)-2'-deoxyuridine base substitution. Both showed enhanced in vitro
TFO binding, increased repair in cell-free extracts, and increased recombination in
episomal targets in an XPA-dependent manner. Several other chemical modifications
showed enhanced binding but did not show increased repair or recombination.
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These chemically modified TFOs were compared to purine m otif TFOs for their
ability to induce recombination and repair in a single-copy genomic target. Previously,
the ability o f TFOs to induce recombination between a target locus and a donor DNA was
only demonstrated with multi-copy episomal targets in mammalian cells. In Chapter 3,
we report that the amidate-modified TFO showed similar induced recombination
frequencies compared to the purine TFO in a single-copy chromosomal target. The
induced recombination was sequence-, target-, and dose-dependent with correction
frequencies up to 0.1%.
The final goal o f this work was to create altered helical structures and to examine
where the incisions are made in repair o f these structures. Previous work in the Glazer
lab and work presented in Chapter 2 determined that triplex-induced repair and
recombination requires XPA, a NER recognition factor [95, 104, 105], A 10 nucleotide
TFO, conjugated to psoralen, and monoadducted to duplex DNA produces excision
products, while a 30 nucleotide TFO does not produce excision products [106]. The
nature of these excision products and the location o f the incisions have not been
previously evaluated. This idea is also consistent with the fact that the length of
attachment o f some TFOs (i.e. TFOs 30 nucleotides long) exceeds the canonical excision
span of NER. In order to understand the mechanism o f triplex action and to elucidate the
pathway by which triplexes promote repair and recombination, the incision sites in repair
of the bulky adduct created by triplex binding need to be mapped. TFOs o f different
lengths will be tested to determine the length limitation for NER to excise the triplex. In
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Chapter 4, altered helical structures using a variety o f substrates (linear and plasmid)
were evaluated in conjunction with TFOs to help develop an assay to understand the
nature o f incisions made in repair o f a triplex.
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Figure 1. Triplex-Binding Code and Orientation. (A) In the purine motif, triplexforming oligonucleotides bind in an anti-parallel orientation via reverse Hoogsteen
bonds. (B) In the pyrimidine motif, the third strand binds in a parallel orientation via
Hoogsteen bonds. The canonical triplets are shown for each motif.
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Figure 2. Peptide nucleic acid (PNA) binding to duplex DNA. (A) PNAs consisting
o f cytidine-rich polypyrimidine sequences bind as third strands through Hoogsteen
bonds. (B) PNAs can also bind as third strands in conjunction with a PNA that strand
invades (binding via Watson-Crick base pairing to one strand o f the duplex DNA). When
the strand invading and triplex-forming strands are tethered together, they form a PNA
clamp. Homopurine PNAs bind through single strand duplex invasion (C) or double
strand (D) duplex invasion o f the DNA. This figure was adapted from Nielson, P.E.,
(2001). Current Opinion in Biotechnology, 12: p. 16-20.
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Figure 3. TFO-induced gene modification. (A) TFO-directed mutagenesis. TFOs can
be used for site-specific delivery o f DNA reactive conjugates such as psoralen. TFOs
also induce mutations around the TFO binding site independent o f conjugation to reactive
agents. (B) TFO-induced recombination. TFOs have been used in a variety o f
intramolecular and intermolecular targeting. Intramolecular targeting involves gene
correction through recombination between tandem differentially mutated genes located
on opposite sides o f a TFO binding site. Intermolecular targeting relies on either a
tethered or untethered donor molecule for the wild-type correction o f the mutation.
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Figure 4. Protocol for detecting chromosomal mutations in TFO treated mice.
Transgenic reporter mice containing multiple copies o f chromosomally integrated lambda
supFGl (containing a triplex target site) and a control gene ell (lacking a triplex target
site) were intraperitoneally (IP) injected with TFO for 5 consecutive days. Ten days later
genomic DNA was isolated from a variety o f tissues. Mutagenesis was detected by in
vitro packaging of the phage followed by plating on a bacterial lawn (on plates containing
IPTG and X-Gal). Mutant plaques were white while wild-type plaques were blue.
Mutant plaque DNA was isolated and sequenced.
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Figure 5. Reporter gene constructs for recombination. (A) Tandem supF genes for
psoralen-AG30 TFO targeting. Episomal target for transient transfection in COS-7 cells.
The SupF gene upstream o f TFO target site was mutated at base pair (bp) 163, the
downstream SupF gene was mutated at bp 115. (B) Dual thymidine kinase genes. A
chromosomal target in mouse cells for induced recombination with two tandem mutated
copies of the herpes simplex thymidine kinase (TK) gene. (C) The luciferase reporter
construct used in the distance experiments. The TFO target site is 40 bp upstream o f the
gene start site and mutations in the firefly luciferase gene at the different distances are
indicated (13 bp, 242 bp, 753 bp, 1255 bp).
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Introduction
TFOs provide potential tools for altering gene function by either repressing
transcription, inhibiting DNA replication, or inducing site-specific mutagenesis and
recombination [1-6]. TFOs bind in the major groove of DNA in a sequence-specific
manner to polypurine/polypyrimidine sequences, in two distinct motifs [7-10]. TFOs in
the purine m otif bind anti-parallel to the purine strand o f the duplex via reverseHoogsteen hydrogen bonds and TFOs in the pyrimidine m otif bind in a parallel
orientation via Hoogsteen bonds [7-10], The third-strand binding code specifies that in
the purine m otif G and A in the third strand bind to the duplex G and A, respectively;
while in the pyrimidine m otif C and T bind to the duplex G and A, respectively [11].
Binding affinity in the two motifs is differentially affected by pFI and ion
concentrations. In the pyrimidine motif, the need for protonation o f cytosines at the N3
position (favored at low pH) limits the binding affinity o f TFOs composed o f unmodified
DNA under physiological conditions [12]. In order to make TFOs more effective tools,
chemical modifications have been developed to enhance third-strand binding under in
vivo conditions. Base modifications such as 5-methyl-2'-deoxycytidine (5meC) and 5-(lpropynyl)-2'-deoxyuridine (pdU) and sugar modifications such as 2'-0-(2-aminoethyl)ribose (2'-AE) substitution improve binding affinity and psoralen delivery in the
pyrimidine m otif [13, 14]. Pyrimidine TFOs with a N3'->P5' phosphoramidate (amidate)
backbone (in which nitrogen replaces the bridging 3' oxygen o f the diester) have also
been shown to form stable triplexes at neutral pH [15].
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In addition, conjugation o f intercalators such as pyrene and acridine to TFOs has
been shown to further increase their biological activity [16]. Although purine TFOs
consisting o f standard DNA (except for 3'-end-capping [4, 17]) have been shown to be
active in cells and animals [16-18], fewer strategies have been established for effective
modification of purine TFOs. The most effective option that has been demonstrated is
backbone substitution with N, N-diethylethylenediamine (DEED) intemucleoside
linkages which reduce the Mg2+-dependence and enhance intracellular activity of
polypurine TFOs [18].
Both purine and appropriately modified pyrimidine TFOs have been used to direct
psoralen intercalation and photoadduct formation to specific sites in mammalian cells and
yeast [16, 17, 19], In the absence o f psoralen, however, only purine TFOs have been
shown to induce genomic changes (either mutagenesis or recombination) via the effects
o f third-strand binding alone [4]. Previous work has demonstrated that non-covalent
triplexes formed by purine TFOs are active in stimulating repair and recombination in
cell-free extracts, in cell culture, and even in mice [3,5, 20, 21]. Studies in human cellfree extracts and in DNA repair-deficient human cell lines have revealed the ability of
non-covalent purine m otif triplexes to provoke recombination in a manner dependent on
the nucleotide excision repair (NER) pathway [4], ITowever, the ability o f non-covalent
triplexes formed by pyrimidine TFOs to induce recombination has not been established.
In the work reported here, we sought to determine the extent to which triplexes
formed by pyrimidine TFOs can stimulate recombination and repair. Because standard
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DNA TFOs bind poorly in the pyrimidine motif, we evaluated TFOs containing a series
of modifications to determine which, if any, are effective in provoking DNA metabolism
via third-strand binding alone, in the absence o f a DNA-reactive conjugate. Interestingly,
although several modifications did support high affinity binding under physiological
conditions in vitro, only amidate and pdU-modified TFOs induced recombination in
episomal targets in cells and repair in cell-free extracts. These results demonstrate that
certain pyrimidine TFOs can provoke recombination without the need for covalent
damage to the DNA. Because pyrimidine triplexes are favored at A:T bp-rich sites (in
contrast to purine triplexes, which are favored at G:C rich sites), these findings increase
the number o f potential genomic target sites suitable for modification by non-covalent
triplexes. In addition, we propose a model in which TFO sugar substitution at the 2'
position may influence the extent to which the resulting triplex can provoke DNA
metabolism, with reference to NMR studies showing that 2' substitution of the TFO
influences the degree o f structural distortion o f the duplex to which the TFO is bound
[22],

Materials and Methods
Oligonucleotides and Vectors
Oligonucleotides were obtained from Transgenomic (am idatel8), Gilead Sciences
and Eurogentec (G3pUmC18), Oligos Etc. (G3TmC18, 2'-0-M el8), Proligo (LNA18,
LNAcontrol) and Eurogentec (LNA18), Eurogentec (UmCcontrol), Gene Tools
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(m orphl8), Midland Certified Reagents Company (AG30, SCR30, MIX30, as51),
Rowshon Alam and Michael Seidman (2-AE), Chip Greaves and Dan Weeks (DEED),
and Keck Oligonucleotide Synthesis Facility (Yale University) (AG19, DNA18). Duplex
target oligonucleotides (G3Y, G3R) were synthesized by Oligos Etc. When the chemical
modification did not provide protection against exonuclease degradation, which is
necessary for cell targeting experiments, 3'-ends were synthesized to contain a 3'
propylamine group, using the C3 amino-CPG from Glen Research. The following
oligonucleotides contain a 3' propylamine group: G3TmC18, G3pUmC18, AG30,
SCR30, and MIX30. Three terminal phosphorothioate linkages were synthesized on the
3'-end o f 2 '-0 -M el8 and as51 has terminal phosphorothioate linkages on both ends.
Pyrimidine TFO sequences and modifications are listed in Fig. 1. The sequences for the
control oligonucleotides are as follows: AG30, 5'AGGAAGGGGG GGGTGGTGGG
GGAGGGGGAG 3'; SCR30, 5’ GGAGGAGTGG AGGGGAGTGA GGGGGGGGGG
3’; MIX30, 5' AGTCAGTCAG TCAGTCAGTC AGTCAGTCAG 3'; UmCcontrol, 5’
cucucucucuuuuuuu 3' (c = 5meC, u = pdU); L N A control, 5' TtTTCtTTTtTCTtTTCt 3'
(t = LNA); AG19, 5'AGGAAGGGGG GGGTGGTGGG 3'; DNA 18, 5' TTTTCTTTTT
TCTTTTCT 3'. And the single-stranded donor, as51, had the sequence: 5'
TGGTAAAGCC ACCATGGAAG ACGCCAAAAA CAT A A AGAAA
GGCCCGGCGCC 3'.
The pSupFTC18 shuttle vector, derived from pSP189 [23], carries two copies o f
the supF gene, each with a distinct mutation, flanking an 18-bp A-rich
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homopurine/homopyrimidine target site (the T C I8 site from pLSG3 [13]). These
mutations were created using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene). These mutations result in inactive tRNAs which lack the ability to suppress
the amber mutation in the lacZ gene in MBM7070 E. coli which are used as indicator
hosts for this recombination assay [24],
The plucTC18 vector was derived from a plasmid constructed by subcloning the
firefly luciferase gene Fluc+ (pGL3-Basic Vector, Promega) into pcDNA5/FRT
(Invitrogen) [25]. The TCI 8 target site was inserted 40 bp upstream o f the Fluc+ start
site. Site-specific mutagenesis was used to create a stop codon at bp 13 downstream from
the start codon.
The pRLTC18 vector was constructed by adding the TFO target site (the T C I8
site from pLSG3 [13]) into the multiple cloning region o f the pRL-CMV vector
(Promega).
Third-strand binding assays
Third-strand binding was measured using gel mobility shift assays under native
conditions. Two complementary 30-mers (G3Y, G3R) containing the T C I8 target from
pLSG3 (representing bp 76 to 105) were synthesized. Duplex DNA was prepared by
mixing 1000 pmol o f each 30-mer together with 50 mM NaCl and incubating at 85°C for
20 minutes and cooling to room temperature before end-labeling with T4 polynucleotide
kinase (New England BioLabs) and [y-32P]ATP (Amersham Biosciences). Duplex was
gel purified, electroeluted, and filtered by Centricon (Millipore). A fixed concentration
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o f duplex at 5 x 10"8 M was added to binding reactions with increasing concentrations of
oligonucleotides in 20 pi o f 10 mM Tris (pH 7.2) and selected concentrations of MgCl2
(0.1 mM or 10 mM) and KC1 (0 mM or 140 mM). Binding for full DEED 18 was carried
out at pH 7.6 with the addition o f 1 mM spermine. Binding assays were also carried out
at pH 5.4, in which case 40 mM Tris-acetic acid was substituted for Tris base at pH 5.4.
Samples were incubated at 37°C for 16 hours unless otherwise specified.
Samples bound at pH 7.2 were loaded onto 15% polyacrylamide gels
[acrylamide/bisacrylamide (19:1)] containing 17.8 mM Tris and 17.8 mM boric acid (pH
7.2) and 10 mM MgCF and the gels were run in the same concentration o f Tris-boric acid
and MgCl2 at 60 V for

6

hours at 23°C. For samples bound at pH 5.4, 15%

polyacrylamide gels containing 40 mM Tris-acetate and 10 mM MgCl2 were used and
gels were run in buffers o f the same concentration of Tris-acetate and MgCF at 60 V for
6

hours at 23°C.

Shuttle vector recombination assay
Monkey COS-7 cells were obtained from ATCC (1651-CRL) and grown in
DMEM/10% fetal bovine serum (FBS) (Gibco). Cells were grown to 50-70% confluency
and cell transfection was performed with GenePORTER2 (Gene Therapy Systems, Inc.).
Cells were transfected with 1 pg o f pSupFTC18 followed 24 hours later by a second,
separate transfection with

1

pg o f oligonucleotide. Cells were harvested at 48 hours after

oligonucleotide transfection and shuttle vector DNA was isolated by a modified alkaline
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lysis procedure, as previously described [6 ], Vector samples were used to transform
indicator bacteria (MBM7070 [lacZ(Am)] [23]) by electroporation (Bio-Rad gene pulser;
settings: 25 pF, 250 W, and 1800 V; 0.1 cm electrode gap cuvette), and colonies were
screened for supF function by growth on plates supplemented with 75 pg/ml ampicillin,
210 pg/ml 5'-bromo-4-chloro-3-indolyl-(3-D-galactopyranoside (X-Gal), and 200 pg/ml
IPTG (isopropyl-P-D-thiogalactopyranoside). Recombination events were indicated by
wild-type blue colonies in a background o f white colonies.
CHO cell transfection and luciferase assay
CHO cells were obtained from Invitrogen and grown in F12/10% FBS (Gibco)
supplemented with 2 mM L-glutamine (Gibco) and 100 pg/mL Zeocin (Invitrogen).
CHO cells were transfected and the luciferase activity was assayed as previously
described [25]. Briefly, 24 hours prior to transfection, 12-well plates were seeded with
5 x 104 cells/well. plucTC18 was preincubated overnight with as51 (an oligonucleotide
containing the wild-type luciferase sequence for the mutated region) and the TFO to be
tested with 10 mM MgCF and 10 mM Tris pH 7.2 at 37°C. Cells were transfected with
GenePORTER2 as described above. Each transfection delivered 0.3 pg o f plasmid,
donor, and TFO per well. Cells were collected 48 hours post-transfection by rinsing
twice with PBS followed by lysis with lx Passive Lysis Buffer (Promega). Luciferase
activity was measured using the Promega Dual Luciferase Kit and only the LAR II
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substrate. The total protein in the cell lysate was determined via Bradford protein assay
[26].
In vitro repair synthesis assay
Repair reactions were carried out as described [27], with several modifications.
HeLaScribe Nuclear Extract in vitro Transcription Grade (Promega) was used. The
pRLTC18 plasmid (500 ng) containing the T C I 8 target sequence was preincubated with
1 pM TFO (37°C, 18 hours, 10 mM Tris, pH 7.2, 10 mM MgCU). As a positive control,
one sample was incubated with sterile water in place o f oligonucleotide, this sample was
then damaged by UVC radiation treatment (2 inches, 30 seconds). The DNA was added
to HeLa cell-free extracts with [a- 3 2 P]dCTP (Amersham Biosciences) and supplemented
as previously described [27], Samples were incubated for 3 hours at 30°C and the
reactions were stopped as previously described [27]. Substrate plasmid DNAs were
isolated from the reaction by phenol/chloroform/iso-amyl alcohol extraction and ethanol
precipitation. The isolated vector DNAs were linearized by Xho I digestion and the
samples were analyzed by gel electrophoresis. DNA repair synthesis was quantified by
measure of [a - 3 2 P]dCTP incorporation using a phosphorimager (Storm 860, Molecular
Dynamics, Amersham Pharmacia Biotech). The quantified value o f the UVC treated
sample was set to

1 0 0

% and used to normalize the measurements o f the other samples.

Shuttle vector assay in repair-deficient and corrected cells
XP12BE cells (deficient in the nucleotide excision repair factor, XPA) were
obtained from Coriell Cell Repositories (GM04429) and grown in MEM/10% FBS
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(Gibco). The shuttle vector recombination assay was performed as described above
except that in some cases the cells were also transfected with

1

pg o f a plasmid

containing XPA cDNA (XPA cDNA with a His tag on the C-terminus cloned into the
multiple cloning site o f pcDNA3.1 (Invitrogen)) at the same time the cells were
transfected with the psupTC18. XPA expression was verified by Western blot. Briefly,
cells were lysed (at 48 and 72 hours post-transfection) with RIPA buffer (150 mM NaCl,
0.1% SDS) and 100 pg o f total protein per sample was resolved on 12% SDS/PAGE gels.
Proteins were detected by standard immunoblot procedures using XPA [28] and tubulin
(clone B-5-1-2; Sigma) primary antibodies.
Serum stability assay
Each oligonucleotide was 5'-end-labeled at a concentration o f 1 pM with
[y-3 2 P]ATP using T4 polynucleotide kinase (New England BioLabs) for 1 hour, followed
by heat inactivation for 20 minutes at 70°C. 5 pi o f end-labeled oligonucleotide were
added to 100 pi o f FBS (Gibco) and incubated at 37°C. Aliquots were removed at 0 to 24
hours and added to an equal volume o f formamide dye, before being run on a

2 0

%

denaturing polyacrylamide gel. Visualization and quantification o f intact oligonucleotide
was done using a phosphorimager.
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Results

TFO target site and oligonucleotide modifications
To examine the ability o f triplexes formed in the pyrimidine, parallel m otif to
induce recombination and repair, we evaluated a series o f chemically modified
pyrimidine TFOs each designed to bind to an 18 bp A-rich duplex target site (Fig. 1).
The modifications included amidate and DEED internucleoside linkages and 5meC and
pdU base substitutions. Sugar modifications included 2 '-0 , 4'-C-methylene bridged or
locked nucleic acid (LNA), 2'-0-methyl-ribose (2'-0-M e), and 2'-AE substitutions.
Morpholino (morph) TFOs consist o f both sugar and backbone changes (Fig. 1).
We chose these modifications because either they have been shown to enhance
intracellular delivery o f psoralen conjugates to target genes [amidate [29-33], DEED
[18], 5meC [13, 34], pdU [13, 34, 35], 2'-0-M e [14], and 2'-AE [14]] or they have been
found to provide enhanced third-strand binding in vitro [LNA [36-38] and morpholino
[39, 40]]. In the case o f the DEED modification, enhanced chromosome targeting has
been demonstrated only in the purine motif. However, the ability o f the DEED
internucleoside substitution to confer a potentially advantageous positive charge on the
TFO prompted us to consider pyrimidine TFOs with either full or partial DEED
modifications.
Unless otherwise specified, all TFOs contained phosphodiester backbones. In
some cases all nucleotides were modified in a given TFO while in other cases only
selected ones were modified, as indicated (Fig. 1). The C’s in G3TmC18, G3pUmC18,
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2'-0-M el8, and 2'-AE18 were substituted with 5meC, because this modification has been
shown to enhance third-strand binding at physiological pH [41, 42] and U’s in 2'-AE18
contained 5-methyl-2'-deoxyuridine modifications. Nucleotides in2'-A E18 not
containing the 2'-AE modification were synthesized to contain 2'-0-M e modifications.
In vitro binding measurements
The binding affinities o f TFOs with the modifications described above were
compared under a series o f conditions as determined by gel mobility shift assays in non
denaturing gels. Binding was quantified and equilibrium dissociation constants (K fs,
representing TFO concentrations yielding half-maximal binding) were determined.
Because stable triplex formation is dependent on Mg

2+

_|_

and sensitive to K [43, 44], we

tested binding in either 0.1 or 10 mM MgCF and either 0 or 140 mM KC1 (both
conditions at pH 7.2). In recognition o f the possible pH dependence o f binding by certain
TFOs, we also tested binding at pH 5.4 (in 10 mM MgCF and without KC1).
Under conditions where the minimally modified TFO, G3TmC18, formed
triplexes (pH 5.4, 10 mM MgCF, 0 mM KC1), all o f the chemically modified TFOs
formed triplexes (Fig. 2). However, there was a range o f binding affinities (Fig. 2 and
Table 1). The best binding was seen with the amidate, LNA, 2'-AE, pdU, and 2'-0-M emodified oligonucleotides, with K f s o f 2.8xlO"10, 3.0x10"’°, 4xlO"10, 4.5xlO"10, and
4.6xlO " 10 M, respectively (Fig. 2 and Table 1). G3TmC18, m o rp h l 8 , and partially
modified DEED oligonucleotides showed lower binding affinities, and the full DEED 18
showed the lowest binding affinity (Fig. 2 and Table 1).
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At neutral pH with 10 mM M gCh, the 2'-0-M e, LNA, 2'-AE, and amidate modified TFOs showed strong binding with Kd’s o f 1.5xlO'10, 2.7xlO '10, 6 .0 x l0 '10, and
8.0xl0 ' 10 M, respectively (Fig. 2 and Table 1). The pdU and 5meC-modified TFOs
showed approximately 10-fold weaker binding and the morpholino-modified TFO
showed 1000-fold weaker binding. Neither o f the DEED-modified oligonucleotides
(partial or full) showed any binding at neutral pH.
Under physiological conditions (pH 7.2, 0.1 mM MgCL, and 140 mM KC1), the
amidate, 2'-AE, LNA, and pdU-modified TFOs showed the strongest binding with Kd’s
o f 1.0x1 O'8, 2.0xl0‘8, 2.5xl0'8, and 9.0xl0 ' 8 M, respectively. G3TmC18 showed slightly
weaker binding, and the morpholino and the 2'-0-M e-m odified TFOs showed even
weaker binding. The DEED-modified TFOs showed no detectable binding under these
conditions.
TFO-induced recombination in COS-7 cells
To test triplex-induced recombination by pyrimidine TFOs, we constructed a
SV40-based shuttle vector similar to pSupFAR used in previous work to test purine TFOs
[20]. However, in this case, we designed the vector to contain the 18 bp A-rich target site
used in the binding assays above. This site is inserted between two copies o f the supF
gene, each with an inactivating point mutation, at bp 163 in the upstream gene and at bp
115 in the downstream gene (Fig. 3A). The 5' mutation is 33 bp from the beginning o f
the TFO binding site while the 3' mutation is 24 bp away from the end o f the site.
Recombination between the two genes can generate a functional supF gene, which can be
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scored upon shuttle vector transformation into indicator bacteria following vector DNA
rescue from the COS-7 cells.
The plasmid vector was pre-transfected into the COS-7 cells to establish the
episomal target in these cells. One day later, the cells were transfected with the TFOs
and maintained in culture for 48 hours to allow for triplex formation and possible induced
recombination. As a negative control to establish the background frequency of
recombination in this assay, we included in each experiment cells transfected with vector
but mock transfected the next day without TFO. The vector DNAs were harvested from
the cells and analyzed for recombination events (Fig. 3B). The results were normalized
between experiments by comparison to the plasmid only (no oligonucleotide) background
and presented as recombination frequency. Transfection o f cells with the amidate 18 and
G3pUmC18 TFOs gave the highest levels o f induced recombination, at 0.37% and
0.31%, respectively; whereas G3TmC18, 2'-AE18, and m o rp h l 8 gave lower frequencies
of 0.14%, 0.14%, and 0.13%, respectively. The 2'-0-M e, TNA, and DEED TFOs had
minimal effects over background. The control TFOs, UmCcontrol, LNAcontrol, AG30,
SCR30, and MIX30 showed little effect over background.
To further control for sequence specificity, we tested induced recombination by
the amidate 18 and G3pUmC18 TFOs using a different shuttle vector, pSupFAR, as a
target in the cells. pSupFAR contains two mutant supF genes flanking a 30 bp G-rich
polypurine target site suitable for triplex formation in the purine m otif [3]. In previous
work, we have shown that a G-rich TFO, AG30, can bind with high affinity to the third-
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strand binding site in pSupFAR [3]. AG30 shows no detectable binding to the A-rich
polypurine site found in pSupFTC18, and conversely, TC-rich pyrimidine TFOs show no
binding to the G-rich site in pSupFAR (data not shown). We found that while
transfection of am idatel 8 and G3pUmC18 into COS-7 cells can induce recombination in
pSupFTC18, neither has an effect on recombination in pSupFAR in the same cell assay
(nor do any o f the other modified pyrimidine TFOs tested) (Fig. 4). In contrast, AG30
can induce recombination in pSupFAR in COS-7 cells but has no effect on recombination
in pSupFTC18 (Fig. 4). Hence, the effects o f the am idatel 8 , G3pUmC18, and AG30
TFOs are sequence-specific, based on both oligonucleotide and target site controls.
TFO-induced recombination in CHO cells
To test pyrimidine induced recombination in a different episomal target, we
constructed the plucTCl 8 plasmid, which is a vector containing a pyrimidine TFO target
adjacent to a mutated firefly luciferase reporter gene, similar to a vector used in previous
work studying targeting in the purine m otif [25], The TFO binding site is 40 bp upstream
from the start site of the luciferase gene, and a nonsense mutation that inactivates the
luciferase gene is 13 bp downstream from the start site. In this assay, recombination
induced by TFO binding occurs between the plasmid and a separate donor
oligonucleotide (a 51 -mer) containing the wild-type luciferase sequence in the region o f
the mutation. The amidate 18 was found to induce recombination at a frequency o f 0.11%
(Fig. 5B), whereas the 2'-0-M e and 2'-AE-modified TFOs showed minimal levels o f
induced recombination above background.
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Pyrimidine TFO-induced repair in HeLa cell-free extracts
Because previous work had shown a correlation between the ability o f purine
TFOs to induce recombination and the ability o f the triplexes they form to induce repair,
we assayed for induced repair synthesis in FleLa cell-free extracts on plasmid substrates
containing pyrimidine m otif triplexes. The substrate for DNA repair was a plasmid
incubated in the presence or absence o f TFO. The amount o f DNA repair-associated
synthesis was measured based on the level o f incorporation o f [a- 3 2 P]dCTP into the
plasmid. This is a well-established assay for measuring repair provoked by a variety o f
DNA lesions [45-47]. A m idatel 8 and G3pUmC18 showed the highest level o f induced
repair activity at 42% and

6 6

%, respectively, as compared to UVC damage set at 100%

activity (Fig. 6 A and 6 B). G3TmC18 and LNA18 produced lower repair activity (Fig.
6

A and 6 B).

Pole o f nucleotide excision repair in induced recombination
To determine if the induced recombination in cells by the amidate 18 TFO is due
to the NER pathway, a shuttle vector assay similar to that used in COS-7 cells, above,
was performed in XP12BE cells. These cells are SV40 transformed fibroblasts isolated
from a patient lacking the Xeroderma Pigmentosum, complementation group A protein
(XPA, a recognition protein in the NER pathway). The amidatel 8 TFO was unable to
induce recombination in XP12BE cells (Fig. 6 C). Elowever, with the expression o f XPA
cDNA, induced recombination by amidatel 8 was detected (Fig. 6 C). The expression of
XPA in the cDNA-transfected cells was confirmed by Western blot (Fig. 6 D).
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Nuclease resistance o f pyrim idine TFOs
To test the possibility that differences in resistance to nucleases o f the various
TFOs could be responsible for the observed differences in induced recombination
frequencies, we tested the stability of selected TFOs in serum. The 5'-end-labeled TFOs
were added to FBS and aliquots were removed at time points from 0 to 24 hours to
measure the quantity o f full-length oligonucleotide by gel electrophoresis and
autoradiography. After 1 hour in serum, most o f the chemically modified pyrimidine
TFOs were intact, except for the unmodified-TFO DNA18 and the 5meC-modified TFO
G3TmC18 (Fig. 7). After 3 hours, the am idatel 8 , TNA18, 2 '-0 -M el8 , 2'-AE18, and the
G-rich TFOs all showed greater than 50% remaining intact. The G3pUmC18 TFO
showed around 36% oligonucleotide intact at 3 hours. By

6

hours only the 2'-AE18 and

the am idatel 8 pyrimidine m otif TFOs showed greater than 50% intact; the G3pUmC18
TFO showed about 25% intact. In all cases, less than 10% o f the pyrimidine TFOs
tested remained intact at 12 hours. Interestingly, two G-rich TFOs, AG30 and AG19
showed higher levels o f nuclease resistance, with greater than 50% oligonucleotide
remaining intact at 24 hours (Fig. 7) and persisting at this level even to 72 hours (data not
shown). This serum stability shown by the G-rich TFOs may, in part, account for their
documented effectiveness for gene targeting in vivo following systemic administration in
mice [5].
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Discussion
In the work reported here, we tested a series o f TFOs with selected chemical
modifications for their ability to bind as third strands in the pyrimidine m otif under a
variety o f in vitro conditions, for their ability to induce recombination in two different
cell-based episomal targeting assays, and for their ability to induce repair in cell-free
extracts. We found that high affinity in vitro binding was necessary but not sufficient for
increased intracellular activity. Certain modifications that provide for enhanced in vitro
binding were only minimally effective at increasing the ability o f TFOs to induce
recombination in cells or to stimulate repair in cell-free extracts, while others (amidate 18
and G3pUmC18) stood out in the initial screen and their activity held up under close
evaluation (showing both high third-strand binding affinity and effective intracellular
activity). These differences cannot simply be attributed to differential nuclease
resistance.
The modified TFOs with the highest binding affinities under physiological
conditions in vitro (low Mg2+, high K+, and neutral pH) were amidate 18, G3pUmC18, 2'AE18, and LNA18. O f these, only the amidate and pdU-m odified TFOs mediated
increases in recombination frequencies over background, 3.4 and 2.8-fold, respectively.
The recombination frequencies in the COS-7 episomal shuttle vector assay produced by
am idatel 8 (0.37%) and G3pUmC18 (0.31%) are comparable to the recombination
frequency induced by AG30 in a similar shuttle vector assay (0.40%). These
recombination frequencies are based on targeting an episomal not a chromosomal target.
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Transfection o f the episomal target 24 hours prior to oligonucleotide transfection allowed
for chromatin assembly on the target plasmid [48], In the purine motif, similar
mutagenesis and recombination frequencies have been established in episomal and
chromosomal targets using G-rich TFOs with both targets [4, 6 , 17, 49].
Using a second episomal targeting assay based on intermolecular recombination
in a luciferase reporter gene, similar results were seen with the amidate 18 TFO, with a
recombination frequency o f 0.11% (which is a 48-fold induction o f recombination
compared to recombination by donor DNA alone in this assay). Thus, in two distinct
episomal targeting systems in cells, the amidate 18 TFO was seen to induce
recombination in the absence o f covalent adduct formation.
Additionally, the amidatel 8 and the G3pUmC18 TFOs induced repair in cell-free
extracts. In cells, the induction of recombination in the shuttle vector assay by
amidate 18 was found to be dependent on XPA, consistent with the in vitro repair results
and further suggesting that triplexes formed by amidate 18 induce recombination in a
repair-dependent manner.
Hence, while several o f the chemically modified TFOs in the pyrimidine m otif
were found to bind well as third strands under physiologic conditions in vitro, only the
amidate 18 and G3pUmC18 TFOs were seen to induce recombination and repair. One
explanation consistent with our results would be that the triplexes formed by the 2'-AE
and LNA-modified TFOs are less effective at provoking DNA repair and thereby less
effective at inducing recombination. Our prior work with purine m otif TFOs indicated

2.19

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

J. M. Kalish
that triplexes can be recognized as “lesions” in the DNA by factors in the NER pathway,
leading to induced repair and recombination [4, 20, 27], Our current results suggest that
the same is true for the pyrimidine m otif triplexes formed by amidatel 8 or G3pUmC18
TFOs.
Conceptually, this recognition is likely to result from helical alterations caused by
triplex formation [50], Interestingly, Asensio et al. [22] found in an NMR-based
structural analysis o f pyrimidine m otif triplexes that the degree o f duplex helical
distortion can be influenced by substitutions at the 2'-position o f the ribose on the TFO.
Comparing TFOs with 2'-deoxy (DNA), 2'-OH (RNA), and 2'-0-m ethyl (2'-0-M e) ribose
moieties, they found that the relative degrees o f distortion were: DNA > RNA > 2'-0-M e.
Hence, RNA-like substitution at the 2'-position in the TFO, which tends to promote a C3endo sugar conformation [51], appears to reduce the helical distortion that occurs upon
third-strand binding.
The TFOs showing the highest levels o f induced recombination were amidatel 8
and G3pUmC18 in the pyrimidine m otif and AG30 in the purine motif. All o f these
contain DNA-like deoxyribose. In contrast, the 2'-AE18 and LNA18 TFOs have RNAlike 2'-substituted sugars. In fact, the LNA 2' substitution (consisting o f the 2'-0, 4'-Cmethylene bridge) locks the ribose into the RNA-like C3-endo conformation [52], This is
proposed to be an advantage for triplex formation because it may serve to pre-organize
the TFO into a uniform conformation favorable to third-strand binding [52], but it may
also serve to minimize the resulting helical distortion. Therefore, based on this model, it
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is possible that the am idatel 8 , G3pUmC18, and AG30 TFOs may create triplexes that are
more distorting than those produced by the 2'-AE18 and LNA18, resulting in an
increased ability o f the resulting triplexes to provoke DNA repair (as shown) and thereby
stimulate recombination.
In conclusion, the work reported here demonstrates that non-covalent pyrimidine
TFOs, when appropriately modified, can mediate high affinity binding, induction of
recombination in cells, and induction o f repair in cell-free extracts, at levels similar to
those seen with G-rich purine TFOs at their respective target sites. These results expand
the number of possible reagents for targeted genome modification.
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The majority o f this work has been published and the reference is: Kalish, J.M., et al.,
Triplex-induced recombination and repair in the pyrimidine motif. Nucleic Acids
Research, 2005. 33(11): p. 3492-502.
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Figures and Tables

Table 1. B inding o f chem ically m odified pyrim idine oligonucleotides to an
18 bp A -rich site/'

oligonucleotide
a m id atelS
pD E E D 18
full D E ED 18
G 3Tm C 18
G 3pU m C 18
2 '-0 - M e l8
2'-A E18
L N A 18
m orph 18r

pH 5.4
10 m M M gC l2
0 m M KC1
2.8
3.0
1.0
3.0
4.5
4.6
4.0
3.0
3.0

x
x
x
x
x
x
x
x
x

10 10
10 s
10-B
109
1 0 1()
10 10
10 10
10-10
10 s

pH 7.2
10 m M M g C l2
0 m M KC1
8.0 x 10 10
none
n one1’
7.0 x 1 0 9
7.0 x lO'9
1.5 x 10 19
6.0 x 10 10
2.7 x 10 10
3.5 x 1 0 6

pH 7.2
0.1 m M M gC l,
140 m M K C f
1.0 x 10 s
none
none
3.0 x 1 0 7
9.0 x 10 s
8.0 x 1 0 3
2.0 x 1 0 8
2 .5 x 1 0 8
5.1 x 1 0 6

a B inding affinities w ere calculated as equilibrium dissociation constants
(K s) under the indicated conditions, as determ ined by gel m obility shift
assay under non-denaturing conditions. K d valu es are g iven in molarity.
B inding w as done for 16 hours at 37"C un less otherw ise specified.
11B inding w as done at pH 7.6 w ith 1 m M sperm ine.
1 B inding w as done at 23°C.
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Duplex target and oligonucleotides
G3Y 5'tcgaggTCTTTTCTTTTTTCTTTTagggggg3'
G3R 3 'agctccAGAAAAGAAAAAAGAAAAtccccccS'
amidatel8
pDEED18
full DEED18
G3TmC18
G3pUmC18
LNA18
2 ' -0-Mel8
2 ' -AE18
morphl8

3'
3'
3'
3'
3'
3*
3'
3'
3'

tcttttcttttttctttt
TcTTTTcTTTTTtCTTTt
tcttttcttttttctttt
TcTTTTcTTTTTTcTTTT
ucuuuucuuuuuucuuuu
TcTtTtCtTtTtTcTtTt
tcttttcttttttctttt
UcuuuUCUUUUUUCUUUU
tcttttcttttttctttt

5
5
5
5
5
5
5
5
5

Figure 1A. Duplex target and oligonucleotide modifications. The third-strand
binding site is indicated in capital letters in the duplex (G3Y/G3R) used for binding
studies. For the oligonucleotides, lower case letters indicate modified nucleotides with
the specific chemistry as indicated in the name o f the oligonucleotide. Upper case letters
indicate unmodified nucleotides. All internucleoside linkages in am idatel 8 are N3'->P5'
phosphoramidate (amidate)-modified. N, N-diethylethylenediamine (DEED)-modified
nucleotides are present in partial DEED (pDEED18) and full DEED 18 as indicated.
G3TmC18 contains 5-methyl-2'-deoxycytidines (5meC) in place o f cytidines.
G3pUmC18 contains 5meC-modifications on all cytidines and all thymines are replaced
by 5-(l-propynyl)-2'-deoxyuridines (pdU). LNA18 contains unmodified nucleotides
alternating with 2'-0, 4'-C-methylene bridged or locked nucleic acid (LNA)-modified
nucleotides. 2'-0-M el8 contains 2'-0-methyl-ribose (2'-0-M e)-modified nucleotides and
all cytidines have 5meC-modifications. 2'-AE18 contains 2'-0-(2-aminoethyl)-ribose (2'AE)-modified nucleotides at the four lower case letter positions, while the upper case
positions have 2'-0-M e-modifications and all positions also have either 5meCmodifications or 5-methyl-2'-deoxyuridine modifications. All nucleotides in m o rp h l 8
are morpholino (morph)-modified.
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Chemical Structures
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Figure IB. Structures of the chemical modifications. N3'->P5' phosphoramidate
(amidate); N, N-diethylethylenediamine (DEED); 5-methyl-2'-deoxycytidine (5meC); 5(l-propynyl)-2'-deoxyuridine (pdU); 2 '-0 , 4'-C-methylene bridged or locked nucleic acid
(LNA); 2'-0-methyl-ribose (2'-0-M e); 2'-0-(2-aminoethyl)-ribose (2'-AE); morpholino
(morph).
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Oligonucleotide Concentration
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Figure 2. Third-strand binding under selected conditions as determined by gel
mobility shift analysis. The first lane in each panel contains duplex alone (0
concentration o f TFO), the second lane contains 10' 5 M oligonucleotide, and each
subsequent column contains a ten-fold dilution. Third-strand binding conditions: (A) pH
5.4, 10 mM MgCl2, and 0 mM KC1; (B) pH 7.2, 10 mM MgCl2, and 0 mM KC1; (C) pH
7.2, 0.1 mM MgCl2, and 140 mM KC1. The bands o f reduced mobility relative to the
duplex alone represent triplex formation.
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Recombination Construct
3 'CACCACCCCAA
5' GTGGTGGGGTT

3' TCTTTTCTTTTTTCTTTT 5'
A
GCCGGCTCTAGAAAA<3AAAAAAGAAAATCTAGACACCA
C
CTTCCAAGCTTA 5'
T -- C GGCCGAGATCTTTTCTTTTTTCTTTTAGATCTGTGGT--- A ---GAAGGTTCGAAT 3 '

SupF163
pBR327
amp

163

115

SupF115
pBR327
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pSupFT C 18
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SV40 T-antigen

0.4

o

c
In
E

oo0 )

0.3

0.2

DC

0.1

0.0

ii

O CO CO 0 0
<13 UJ <
= <-D uj
uj O O
O Q
° 15 UJ LU £ E
s
< z
oc •“O LU LU
CM
O

00

CO 00

■«-“

^ * r -

Q

Q

CL =

oo CO

o

-5

T—

co

9- <
o

cn oon
cr x
O

5;

w s

13
Oligonucleotide

Figure 3. Induced recombination mediated by pyrimidine TFOs. Schematic
representation of the pSupFTC18 vector. This SV40-based vector contains two mutant
supF genes in tandem. The upstream mutant supF gene, supF163, contains a C-to-T
point mutation at nucleotide position 163. The downstream mutant supF gene, supF115,
contains a G-to-A point mutation at nucleotide position 115. In between the two mutant
supF genes is an 18 bp A-T rich homopurine/homopyrimidine target site. The chemically
modified oligonucleotides described in Fig. 1A were designed to bind to this target
sequence. (B) Triplex-induced recombination in COS-7 cells. The plasmid described in
(A) was pre-transfected into COS-7 cells followed one day later by transfection o f the
indicated oligonucleotides or mock transfection. After 48 hours, shuttle vector DNA was
isolated and transformed into indicator bacteria to analyze supF gene function and allow
quantification o f recombination events. Percent recombination was calculated by the
ratio of the number o f blue colonies to total colonies between cells transfected with the
modified TFOs and mock-transfected cells.
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Figure 4. Sequence-specificity of the TFO-induced recombination. (A) Triplexinduced recombination with a pyrimidine m otif target. Cells pre-transfected with the
dual supF plasmid containing the 18 bp A-T rich site, pSupFTC18, were transfected the
next day with lipid reagent alone or with the indicated TFOs. AG30 and SCR30 are Grich TFOs and MIX30 has a mixed sequence. Shuttle vector rescue and analysis were
performed as for Fig. 3. (B) Triplex-induced recombination with a purine m otif target.
Cells pre-transfected with a dual supF plasmid containing a 30 bp G-rich site, pSupFAR,
were transfected one day later with lipid reagent alone or with the indicated TFOs.
Analysis o f recombination events was performed as above. Amidate 18 and G3pUmC18
bind with high affinity to the A-rich target site in the intergenic region in pSupFTCl 8 but
not to the G-rich site in pSupFAR. AG30 binds well to the site in pSupFAR but not to
that in pSupFTC 18.
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Figure 5. Intermolecular induced recombination mediated by pyrimidine TFOs.
(A) Schematic o f the plucTC18 construct. The plasmid contains the pyrimidine triplex
binding site located 40 bp upstream o f the start codon for the firefly luciferase gene. The
luciferase gene has a nonsense mutation at 13 bp downstream from the start codon. (B)
Percent recombination in CHO cells. Plasmid, TFO, and the donor oligonucleotide
(as51) were co-transfected into CHO cells. After 48 hours, cells were lysed and
recombination was measured based on relative light units and normalized to protein.
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Figure 6. Pyrimidine m otif TFOs and DNA repair. (A) Pyrimidine triplex-induced
DNA repair in HeLa cell-free extracts. TFOs and plasmids were co-incubated in HeLa
cell-free extracts supplemented with [a- 3 2 P]dCTP. Induced DNA repair synthesis was
measured by visualization and quantification o f incorporation o f [a - 3 2 P]dCTP into the
plasmid. As a positive control, plasmid alone was treated with UVC irradiation. (B)
Quantification of induced repair as measured by [a- 3 2 P]dCTP incorporation in (A);
normalized to UVC-treated plasmid representing 100% repair activity. (C) Dependence
o f triplex-induced recombination on XPA. XP12BE (XPA-deficient) cells were
transfected with the dual supF reporter construct containing the pyrimidine m otif triplex
binding site and then transfected or not with the amidate 18 TFO. Parallel samples were
also transfected with XPA cDNA at the same time as the dual supF vector. Induced
recombination was assayed as in Fig. 3 and Fig. 4. (D) Levels o f XPA expression in
XP12BE cells versus XP12BE cells transfected with a XPA cDNA construct. XP12BE
cells and XP12BE cells transfected with XPA cDNA were collected at 48 and 72 hours
post-transfection and expression o f XPA was detected by Western blot.
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Introduction
Gene targeting via homologous recombination (HR) is well established as a
research tool to generate knock-out or genetically modified mammalian cells and mice
[1], However, the technology for gene knock-out depends on selection techniques to
enrich for cells in which HR events have occurred and to eliminate cells in which offtarget vector integration has taken place [ 1 , 2 ]; it does not alter the absolute frequency of
targeted HR. For gene therapy applications, such techniques are less useful because the
ability to apply clonal selection to human stem cells is limited. Consequently, most gene
therapy efforts have focused on the introduction o f cDNAs within expression constructs,
typically using viral vectors, to complement inherited genetic defects by gene addition
rather than by HR-mediated gene correction. Integration usually occurs in a non-targeted
manner, often resulting in sub-optimal expression, inactivation, or even loss o f the
construct. Site-specific gene correction by HR would be preferable to ensure appropriate
expression and function.
Several approaches are under study to enhance the frequency o f targeted HR for
eventual application to gene therapy. One involves the use o f single-stranded viral
vectors, such as the adeno-associated virus (AAV), that may undergo homology-directed
integration at increased frequencies [3, 4], However, these vectors can still mediate
significant levels o f non-homologous integration events [3, 4]. Alternatively, studies
have demonstrated that the production of site-specific chromosomal damage can
substantially increase the frequency o f homologous recombination by exogenous DNAs
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[5]. In mammalian cells, evidence suggests that the search for homology is not
necessarily the rate-limiting step for gene targeting [5]. Rather, DNA damage, and in
particular strand breaks, may be the key step to sensitize the target site for HR. Work
using rare-cutting endonucleases such as l-Scel has shown that site-directed double
strand breaks (DSBs) can stimulate HR by 1,000-fold or more [6-11], However, \-Scel is
not applicable to gene therapy because its use requires the prior introduction of its 18-bp
recognition site into the genome.
To overcome this limitation, one approach has been the development of artificial
nucleases with engineered binding domains as tools to create strand breaks at specified
sites. Recent studies have demonstrated that expression o f custom-designed zinc finger
nucleases (ZFNs) in Drosophila embryos or in mammalian cells in culture can be
effective at promoting site-directed recombination [12-15]. However, the off-target
effects o f such ZFNs have not been well-studied.
Another method to create site-specific DNA damage is based on the use o f
triplex-forming oligonucleotides (TFOs). Triplex DNA can be formed when
oligonucleotides bind as third strands in a sequence-specific manner within the major
groove o f the double helix at polypurine/polypyrimidine stretches. In one motif, a
pyrimidine-rich oligonucleotide binds in a direction parallel (in terms o f 5' to 3' direction)
to the purine strand in the duplex [16-19], In this so-called pyrimidine or parallel-motif
triplex, T binds to A:T base pairs (bp) and C binds to G:C bp [16], In the alternative
purine motif, favored at G:C bp-rich target sites, a purine-rich strand binds anti-parallel to
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the purine strand in the Watson-Crick duplex, with A binding to A:T bp and G binding to
G:C bp [20-24],
Initial studies testing the use o f TFOs to induce recombination focused on the
coupling o f the TFOs to DNA-reactive conjugates, such as psoralen, to deliver sitespecific DNA adducts that might provoke recombination [25], However, subsequent
work demonstrated that triple helix formation itself, without any associated covalent
DNA damage, can stimulate recombination via recruitment o f the nucleotide excision
repair (NER) pathway in episomal shuttle vector targets in human cells or in plasmid
substrates in cell-free extracts [26, 27], Studies also demonstrated that there is no
requirement for covalent linkage o f the TFO and the donor molecule, and in the case o f
episomal targets in mammalian cells, there can be substantial distances of several
hundred bp between the TFO binding site (TBS) and the recombination target [28], In
other work, it was shown that intramolecular recombination between tandem repeat genes
at a chromosomal locus can also be induced by TFOs, but intermolecular recombination
was not tested [29, 30],
Here, we report the ability o f TFOs to stimulate intermolecular recombination at a
single-copy chromosomal locus in mammalian cells. CHO-derived cell lines carrying
single copies o f Firefly luciferase (Flue) genes inactivated by stop codon mutations were
co-transfected with TFOs designed to form either parallel or anti-parallel triplexes at sites
upstream of the Flue coding region in combination with single-stranded donor DNAs
(ssDNAs) o f lengths between 30 and 69 nucleotides (nt) carrying wild-type Flue
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sequences. The mixture of the TFOs with the donor DNAs was 5- to 9-fold more
effective at mediating Flue gene correction and restoring luciferase activity than was
transfection o f the donor DNAs alone. Correction frequencies o f up to 0.1% were
obtained in a TFO sequence-, target site-, and dose-dependent manner. The results
establish the utility o f site-directed triplex formation as a tool to boost gene targeting by
donor DNAs at chromosomal sites.

M aterials and M ethods
Oligon ucleotides
Oligonucleotides were synthesized by The Midland Certified Reagent Company
Inc. (Midland, Texas) and purified by RP-HPLC. Oligonucleotide sequences are as
follows: AG30 (5' AGGAAG GGGGGG GTGGTG GGGGAG GGGGAG 3'); 12AG30
(5' GGAGGA GTGGAG GGGAGT GAGGGG GGGGGG 3'); s51 (5' TGGTAAAGCC
ACCATGGAAG ACGCCAAAAA CAT AA AG A A A GGCCCGGCGCC 3'); as30 5'
(CTTTCTTTAT GTTTTTGGCG TCTTCCATGG 3'); as51 (5' GCCGGGCCTT
TCTTTATGTT TTTGGCGTCT TCCATGGTGG CTTTACCAAGC 3'); as69 (5'
CCAGCGGATA GAGTGGCGCC GGGCCTTTCT TTATGTTTTT GGCGTCTTCC
ATGGTGGCTT TACCAAGCT 3'). AG30 and 12AG30 were 3’-end-protected with a
C7 amine group. Flue donor molecules including as30, as51, s51, and as69 were 5’- and
3’-end-protected with three phosphorothioate internucleoside linkages at each end.
Donors with three locked nucleic acid (LNA) residues on each end LNA30, LNA51, and
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LNA69 (of the same sequences as as30, as51, and as69, respectively) were synthesized
by Eurogentec (Seraing, Belgium). Amidate 18 was obtained from Transgenomic as
described [31]. The TC18 sequence o f am idatel 8 was 5'-TTTTCTTTTT TCTTTTCT-3'
and consisted o f phosphoramidate intemucleoside linkages (3' bridging nitrogen) between
all nucleosides. The TFO, LNA18, modified with LNAs at every other residue was also
synthesized by Eurogentec and was o f the same sequence as amidate 18. N, Ndimethylaminopropylphosphoramidate (aDMAP and pDMAP) and
diethylethylenediamine (aDEED) TFOs o f the TCI 8 sequence with these chemistries
between all nucleosides were kindly synthesized by Francoise Debart and Jean-Jacques
Vasseur. (R)-l-0-[4-(l-pyrenylethynyl)phenylmethyl]glycerol, twisted intercalating
nucleic acid (TINA) TFOs TINA849 and TINA855, synthesized by Vyacheslav Filichev,
had the following substitutions 5'ttttPctttt ttctPtttctP3’ and 5'UUUUPCUUUUP
UUCUPUUUPCUa3', respectively, where P is a TINA, a is a C-7 amino group, C is 5methyl-2'-deoxycytidine (5meC), and U is 5-(l-propynyl)-2'-deoxyuridine (pdU) (and c
and t are unmodified nucleobases). Camptothecin (CPT) (topoisomerase I inhibitor)
conjugated TFOs were synthesized by Paola Arimondo. The CPT TFOs all have the
sequence 5'CUCUCUCUCU UUUUUU3’ (where U is pdU and C is 5meC), with a four
carbon linker conjugated to the 3'-end o f the TFO and connected to either 10-carboxy
camptothecin (TUCL4CPT), two phenol rings (TUCL4Ph2), or linker alone
(TUCL4NH2). Psoralen was conjugated to the 5'-end o f TUCL4CPT (psoTUCL4CPT)
and TUCL4Ph2 (psoTUCL4Ph2). The topoisomerase II inhibitors have a (CEFCFFOje
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linker conjugated to the same sequence as above (TUC-C18-ICP165) or to a 20-mer
(5'CUCUCUCUCUUUUUUUCUCU3’, TUC20-C18-ICP165).
Plasm id vectors
Plasmids containing the Flue gene were created by subcloning of Fluc+ from
Promega’s pGL3-Basic Vector (Madison, Wisconsin) into pcDNA5/FRT (Invitrogen, La
Jolla, California) as described [28, 31]. Briefly, an insert containing the duplex AG30
target or the duplex TCI 8 target was introduced upstream o f the Flue ATG start site.
Nonsense mutations were created via site-directed mutagenesis at bp 13 relative to the
Flue start codon. Lack o f luciferase activity in all mutated Flue vectors was confirmed
using the Promega Luciferase Assay (see below).
Cell lines
CHO-Flp cell lines were obtained from Invitrogen (Carlsbad, California) and
maintained according to the manufacturers’ instructions. Cells were transfected with a
1:10 ratio o f the appropriate Flue plasmid to pOG44 (Flp recombinase expression vector)
to generate the following cell lines: CHO-RWT (AG30 purine TFO binding site, wildtype Flue), CHO-R13 (AG30 purine TFO binding site, nonsense mutation at bp 13 of
Flue), CHO-YWT (T C I 8 pyrimidine TFO binding site, wild-type Flue), CHO-Y13
(TCI 8 pyrimidine TFO binding site, nonsense mutation at bp 13 o f Flue), and CHO-YScr
(A:T bp-rich site that has 9 mismatches relative to the T C I 8 site, with the Flue nonsense
mutation at bp 13). CHO-YScr and CHO-YScr202 have the TBS, 5'CUCUCUCUCU
UUUUUU3’ and the Flue nonsense mutation at bp 13 and bp 202 from the start site,
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respectively. Plasmid transfections were carried out using GenePORTER2 Transfection
Reagent (Gene Therapy Systems, San Diego, California). Cells were placed in
nonselective media for 48 hours and then placed into hygromycin selection (600 ug/mL);
colonies were allowed to form and single-copy integration at the expected site was
confirmed via Southern blot [32],
Establishment o f relative light unit standards and determination o f assay sensitivity
Using pairs o f matched cell lines mixed in fixed ratios o f wild-type to mutant Flue
cells, a standard curve was established. Cultures o f matched single-copy Flue wild-type
and Flue mutant cells for each target site set were grown to sub-confluence, detached by
trypsinization, resuspended in medium and counted to establish cell density (cells/mL).
The pairs were mixed as follows: CHO-R13 with CHO-RWT cells and CHO-Y13 with
CHO-YWT cells. The suspensions o f the mutant cells (either CHO-R13 or CHO-Y13)
were adjusted to 1x10s cells per mL, and aliquots o f 50,000 mutant cells were seeded into
individual wells (4 cm 2 /well). Wild-type Flue cells (CHO-RWT or CHO-YWT) were
adjusted to 5 x l 0 4 cells per mT, serially diluted, and then added to the wells containing
the mutant cells. A range o f samples was generated to contain varying proportions of
wild-type cells mixed with the Flue mutant cells

(6

replicates per data point). All cell

cultures were allowed to grow for 48 hours and then the mixed cell populations were
harvested and lysed. The cell lysates were analyzed for luciferase activity using Promega
Luciferase Assay Reagent (Promega, Madison, Wisconsin) according to manufacturer’s
instructions. Relative light units (RLUs) were normalized to the quantity o f protein per
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tested sample. These standards were used as a benchmark for the RLU data. A plot o f
RLU/protein versus percentage o f wild-type cells was generated for each experiment, and
this was used to normalize the experimental data and allow the assignment of
recombination frequencies to the experimental RLU values.
Chromosomal gene targeting protocol and luciferase assay
CHO-R13 or CHO-Y13 cells were transfected with the single-stranded donor
DNA oligonucleotides (ssDNAs) and with selected TFOs (AG30, am idatel 8 , or control
oligonucleotides) using Geneporter 2 according to manufacture’s instructions. Briefly,
2

24 hours prior to transfection, 12-well plates (4 cm per well) were seeded with 5x10

4

cells/well. Quantities of TFOs and donor DNAs transfected were as indicated for each
experiment; in all cases transfections were done in triplicate. Forty-eight hours following
transfection, cells were harvested for lysate preparation and analysis o f Flue gene
correction. Luciferase activity in the lysates was measured as described above. Data are
presented as fold over donor alone for each experiment and as an absolute percent
recombination. The recombination frequency was calculated based on normalization to
the standard curves. For the DEED and DMAP TFOs, cells were electroporated with 2
pM TFO (Bio-Rad gene pulser; settings: 25 pF, 250W, 280 V; in 0.4 cm electrode gap
cuvette) with oligonucleotide on the first day and a fixed amount o f donor was introduced
24 hours later with GenePORTER2. As a positive control am idatel 8 was also
electroporated at a concentration o f 0.5 pM. Cells were lysed and measured for induced
recombination 48 hours after donor transfection as above.
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Results
Design o f reporter cell lines containing a single-copy luciferase gene target
In order to test TFO-induced gene correction in an assay representative o f a
potential gene therapy target, we designed a series o f CHO-derived cell lines each with a
single chromosomal copy of a mutated version o f the Flue reporter gene. In each line,
the Flue locus was engineered to also contain a polypurine/polypyrimidine site amenable
to triplex formation situated upstream o f the coding region and within 71 bp o f the
mutation to be corrected. These cell lines were also engineered such that the Flue
constructs were inserted at the same chromosomal position, an outcome that was
facilitated by use of a parental CHO cell line with a pre-existing Flp recombinase target
(FRT) integrated at a single chromosomal site.
For one pair o f cell lines, an expression cassette containing the luciferase gene
downstream o f the AG30 TFO binding site (at position -53 bp relative to the start ATG o f
the Flue coding region) was sub-cloned into an FRT-containing plasmid vector. A
matching plasmid with a nonsense mutation at bp 13 relative to the ATG start site (siteto-mutation distance of 6 6 bp) was derived by site-directed mutagenesis. These plasmids
were separately used to transfect the FRT-containing CHO-Flp cells in conjunction with
transient expression o f the Flp recombinase. The desired cell lines were selected and
screened as described in the methods section for site-specific integration o f the target
constructs. The resulting cell lines, CHO-RWT and CHO-R13, each were determined to
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contain a single-copy o f the luciferase gene at the standardized integration site, with
either the wild-type Flue or the Flue 13 nonsense mutant, respectively.
Similar steps were performed to generate the CHO-YWT and CHO-Y13 cell lines
containing either the wild-type Flue or the Flue 13 mutant downstream of an A:T bp-rich,
pyrimidine-motif TBS for the TFO, am idatel 8 . In addition, a third mutant cell line,
CHO-YScr, otherwise identical to CHO-Y13 but with a scrambled version o f the TCI 8
site, was established to serve as a target site control. This cell line contains an A:T bprich target which has 9 mismatches relative to the canonical T C I 8 target sequence. The
site-to-mutation distance in both CHO-Y13 and CHO-YScr is 71 bp. The cell line CHOYScr202 has the same TBS as CHO-YScr but the site to mutation distance is 260 bp.
As with the CHO-RWT and CHO-R13 cells, the CHO-Y cell set was confirmed
to have the F/wc-containing constructs integrated into the CHO cell genome at the pre
existing FRT site, as determined by Southern blot analysis (not shown), thereby
facilitating comparisons among the cell lines. Background luciferase enzyme activity
was found to be negligible in lysates from all three o f the cell lines containing the Flue 13
genes with the bp 13 stop codon mutation and from the one cell line containing the
Fluc202 mutation.
Design o f anti-parallel and parallel m otif TFOs
AG30, a G-rich 30-mer TFO, has been previously shown to bind as a third strand
with high affinity in the anti-parallel triplex m otif at the G:C bp-rich duplex target present
in the promoter regions o f CHO-RWT and CHO-R13 (Fig. 1A). The binding
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characteristics o f AG30 for this duplex target have been reported [33], 12AG30 is a Grich 30-mer oligonucleotide containing the same base composition as AG30 but having
12 mismatches in the third-strand binding code. AG30 and 12AG30 consist o f natural
nucleobases and natural phosphodiester backbones except for end-capping with a propyl
amine at the 3'-end to inhibit nuclease degradation. A m idatel 8 is aN 3'->P5'
phosphoramidate modified, T-rich TFO that binds in the parallel triplex m otif to the
polypurine strand o f the duplex target present in the promoter region o f CHO-YWT and
CHO-Y13 (Fig. 1A). It consists o f natural nucleobases but contains a fully substituted
phosphoramidate backbone in which the 3' bridging oxygen is replaced with nitrogen.
This modification has been shown to enhance third strand binding in the pyrimidine m otif
under physiologic conditions [31]. The binding characteristics o f ami date 18 for this
target site have been described previously [31].
The luciferase reporter gene assay is highly reproducible and sensitive
For each experiment, a standard curve was established to correlate luciferase
activity with the proportion o f Flue wild-type cells among Flue mutant cells in mixed cell
populations. Cell lines containing the wild-type copy o f Flue and either the AG30 or
TC18 TFO binding site were mixed in defined ratios from 1:10,000 (0.01%) to 1:3
(33%) with matched cells containing the same TFO binding site but with a mutated
version of the Flue gene. Samples consisting o f all Flue positive (100%) and all Flue
mutant cells (0%) were also included. At each increment o f wild-type cell percentage,
cell lysates were tested for luciferase activity, and RLUs/protein values were determined.
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As shown, there was a highly consistent, linear relationship between RLUs/protein and
percentage o f wild-type cells (Fig. 1C). In addition, this linear relationship was found to
be essentially identical for both pairs o f cell lines; this result is consistent with the fact
that all cell lines were constructed to contain a single-copy of the same basic luciferase
expression cassette in the same genomic locus. The linearity o f the relationship between
luciferase activity and the proportion o f luciferase wild-type cells in mixed cell
populations and the consistency between the two sets o f cell lines provided the basis for
us to compare data between experiments and to assign recombination frequencies based
on luciferase enzyme activity in cell lysates o f treated cells. In addition, the assay was
found to be highly sensitive, being capable of detecting proportional Flue activity (and
therefore recombination events) in just

1

in

1 0 ,0 0 0

cells.

Parallel and anti-parallel m otif TFOs induce sequence-specific recombination between
a genomic target and a single-stranded donor DNA
TFO-induced recombination was tested in both the CHO-R13 and CHO-Y13 cell
lines. The cells were transfected with either the single-stranded donor DNAs alone or
donor DNAs plus specific, mismatched, or unrelated control oligonucleotides. Two days
after transfection, correction o f the luciferase mutation was determined by assaying
luciferase activity in lysates o f the treated cells. As shown (Fig. 2A), AG30 plus donor
induced recombination 5.7-fold over donor alone (0.05% recombination) in the CHOR13 cell line containing the matched G:C bp-rich AG30 binding site upstream o f the
luciferase coding region. However, AG30 had no effect above that o f the donor alone in
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cells containing the A:T bp-rich binding sites (CHO-Y13 or CHO-YScr) at the same
relative position in the luciferase cassette. Specificity was also demonstrated by the lack
o f effect o f 12AG30, an oligonucleotide containing a scrambled version o f the AG30
sequence (creating 12 mismatches to the target sequence in CHO-R13 cells), on donor
DNA recombination in the CHO-R13 cells (Fig. 2A).
Similarly, am idatel 8 induced recombination at a frequency 6.1-fold over donor
alone (0.07% recombination) in the CHO-Y13 cells containing the matched A:T bp-rich
binding site for the am idatel 8 TFO sequence (Fig. 2B) but not in the CHO-YScr cells
(containing an A:T bp-rich binding site with 9 mismatches versus am idatel 8 ). As further
evidence o f specificity, am idatel 8 had no effect on recombination in the CHO-R13 cells
with the G:C-rich binding site (Fig. 2B). Additionally, we also tested LNA18, an
oligonucleotide with the same nucleotide sequence as am idatel 8 but containing modified
2'-0, 4'-C-methylene bridge ribose moieties. This TFO was previously shown to mediate
triplex formation in vitro but to lack intracellular targeting activity [31]. LNA18 did not
induce recombination above that o f the donor alone in the CHO-Y13 cell line (Fig. 2B).
These results show that, in two different CHO cell lines, TFOs can induce intermolecular
recombination at a single-copy genomic locus in a site-specific manner. In addition, the
induced recombination was mediated by both purine and pyrimidine TFOs designed to
form anti-parallel and parallel triplexes, respectively. The specificity o f the reaction was
demonstrated not only by the lack o f stimulation by control oligonucleotides but also by
the inability o f the AG30 and am idatel 8 TFOs to induce recombination at luciferase gene
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loci with mismatched target sites.
TFO induction o f recombination is dose-dependent
Using a fixed amount o f donor DNA per transfection sample o f 0.2 pg/well (~25
nM), the amount of TFO in the transfection mix was incrementally increased from 0.1
pg/well to 0.6 pg/well. In both the CHO-R13 and CHO-Y13 Flue mutant cell lines, there
was a TFO dose-dependent increase in recombination. In the CHO-R13 cells, at the
lowest AG30 dose (0.1 pg/well), the fold induction was 3.8, while at the highest dose
(0.6 pg/well), the fold induction over donor alone was 8.5, corresponding to
recombination frequencies of 0.03% and 0.07%, respectively (Fig 3A). In the CHO-Y13
cells, at the lowest am idatel 8 dose (0 . 1 pg/well). the fold induction o f recombination was
4.7, while at the highest dose (0.6 pg/well), the fold induction was 9.4, correlating to
0.06% and 0.11% recombination, respectively (Fig. 3B).
To exclude the possibility that the dose-dependent effects observed could be
attributable simply to differences in the total quantities o f nucleic acids transfected rather
than the TFO dose, TFO-induced recombination was tested in the setting o f a constant
amount of total nucleic acid transfected per sample (Figs. 3C and 3D). In this
experiment, the sum total amounts o f donor DNA and TFO in the transfection mix were
held constant at 0.6 pg/well; the quantities o f the TFOs and donor DNAs were then
varied in inverse proportion to each other (TFO/donor pairs o f 0.0/0 . 6 pg, 0.2/0.4 pg,
0.4/0.2 pg, and 0.6/0.0 pg). In the CHO-R13 cells, increased recombination was seen
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with higher amounts o f AG30 (Fig. 3C), even in samples with lower amounts o f donor
DNA (except for the sample with no donor DNA); for example, in the samples containing
0.2 pg TFO/O.4 pg donor, there was a 2.1-fold induction; in contrast, samples containing
0.4 pg TFO/O.2 pg donor yielded a 4.1-fold induction. Similarly, with the CHO-Y13
cells, induced recombination was 3.2-fold (over donor alone) when am idatel 8 dose was
0.2 pg/well and 4.4-fold (over donor alone) when am idatel 8 dose was 0.4 pg/well (Fig.
3D). These results further demonstrate the TFO-dependent stimulation of recombination
at the Flue chromosomal loci in the two cells lines.
Donor DNA orientation and length
Previous studies focusing on recombination mediated by ssDNAs alone (without
the use of TFOs) have observed different levels o f activity for DNAs homologous to
either the transcribed or the non-transcribed strand o f the target. Flowever, from target to
target, no consistent preference has emerged [34, 35], We tested whether there was any
preference for donor DNA orientation in our assay in the context o f TFO-induced
recombination. The CFIO-R13 cells were transfected with 0.2 pg/well o f either sense
(matching the non-transcribed strand) or antisense (homologous to the transcribed strand)
single-stranded 51-mer donor DNAs, with or without 0.2 pg/well o f AG30 (Fig. 4A).
AG30 was found to boost recombination over both the sense and anti-sense donors alone,
but the results with the anti-sense donor were superior. Similar results were seen with the
CHO-Y13 cells and the am idatel 8 TFO in the comparison o f sense and antisense donors
(Fig. 4B). Hence, both anti-parallel and parallel third-strand binding induce
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recombination at the F lucl3 target to a greater degree when co-transfected with antisense
versus sense donor DNAs. Antisense donors were used in all the experiments shown in
Figures 2 and 3.
To further examine donor DNA characteristics, we compared TFO-induced
recombination in conjunction with antisense donors o f varying length: as30 (30-mer),
as51 (51-mer), and as69 (69-mer). When co-transfected with am idatel 8 , as30, as51, and
as69 mediated recombination at levels 4.8-, 6.1-, and 3.7-fold over antisense donor alone,
respectively (Fig. 5A). Hence, the short 30-mer donor was found to be active, but length
greater than 51 nt did not necessarily yield increased activity. Additionally, we examined
the effect o f end-modification o f the antisense donors with locked nucleic acids in place
of phosphorothioates at the first and last three positions o f the ssDNAs. The LNAmodified donors were less effective than the phosphorothioate-modified donors (Figures
5B and 5C).
Chemically modified TFOs
Other chemically modified TFOs in addition to am idatel 8 were examined as well.
These modifications included the modified base: 5-(l-propynyl)-2'-deoxyuridine (pdU),
the modified sugars: 2 '-0 , 4'-C-methylene bridged or locked nucleic acid (LNA), and 2'0-(2-aminoethyl)-ribose (2'-AE), and the modified backbones: N, N-dimethylaminopropylphosphoramidate (aDMAP and (3DMAP), N, N-diethylethylenediamine (aDEED),
and (R)-l-0-[4-(l-pyrenylethynyl)phenylmethyl]glycerol, twisted intercalating nucleic
acid (TINA). Chemical modifications and substitutions on the TFOs for the LNA, pdU,
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2'-AE, DEED, and DMAP are shown in Appendix 1. The 2-A E, pdU, and TINA849
showed minimal activity in CHO-Y13 cells compared to am idatel 8 (Fig. 6 A). Several
TINA oligonucleotides were tested but the best induction o f recombination was 2.9-fold
over donor for TINA849. The PDMAP oligonucleotide showed low levels o f induced
recombination, 3.1-fold over donor alone (Fig. 6 B). The aDM AP oligonucleotide
showed slightly higher levels o f induced recombination, 4.0-fold over donor alone (Fig.
6

B). The aDEED oligonucleotide showed 5.7-fold induction o f recombination over

donor (Fig. 6 B). A m idatel 8 showed a 7.7-fold induction o f recombination when
electroporated in parallel with the DMAP and DEED TFOs (Fig. 6 B). Percentages o f
induction o f recombination for the pDMAP, aDM AP, aDEED, and am idatel 8 were
0.037%, 0.049%, 0.068%, and 0.092%, respectively.
The TINA oligonucleotides were also tested for induced recombination in the
episomal targeting assay in COS-7 cells as outlined in Chapter 2. TINA849 did not show
much effect but TINA855 showed an induced recombination frequency o f 0.2%
(compared to 0.37% for am idatel 8 ). Finally, the TINA oligonucleotides were tested for
gene repression in cells containing the wild-type chromosomal target (CHO-YWT cells).
In the Flue cell lines used here, the luciferase gene is driven by a CMV promoter with the
TFO binding site just upstream o f the transcription start site. Thereby assaying for the
level of luciferase expression in the wild-type lines allows for detection of inhibition of
transcription due to TFO binding. The TINA oligonucleotides showed no gene
repression effect.
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In addition to the chemically modified TFOs mentioned above, TFOs conjugated
to camptothecin (CPT) were assessed for their ability to induce recombination or
suppress transcription. Using the cell line CHO-YScr, which contains the target for the
CPT TFOs and a mutation 13 bp from the Flue start codon and the cell line CHOYScr202 (containing a mutation 202 bp from the Flue start codon), the CPT TFOs were
analyzed. Recombination between an antisense donor and the chromosomal target was
induced with the addition o f the camptothecin oligonucleotide (TUCL4CPT) at both
distances in a dose responsive manner (Figures 7A and Fig. 7B). At the 0.2 pg/well TFO
dose, recombination was induced 2.4-fold over donor alone in CHO-YScr cells (Fig. 7A)
and 1.3-fold in CHO-Scr202 cells (Fig. 7B), corresponding to 0.03 and 0.02% induced
recombination, respectively. A greater oligonucleotide concentration was required for a
similar level of recombination to that seen at the 13 bp distance to be seen at the

2 0 2

bp

distance.
Additionally, these oligonucleotides were tested for repression o f wild-type
luciferase activity. Repression observed with the camptothecin oligonucleotide
(TUCL4CPT) was similar to that seen with the TUCT4NH2 and TUCL4NPh2 controls
(Fig. 1C). Minimal repression was seen with the topoisomerase II inhibitor conjugated
oligonucleotides (TUC-C18-ICP165 and TUC20-C18-ICP165) or with the psoralen
conjugated oligonucleotides (psoTUCL4PH2 and psoTUCT4CPT), with or without
psoralen activation (data not shown).
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Discussion
The work reported here demonstrates the ability o f both purine and pyrimidine
m otif TFOs to induce intermolecular recombination by short single-stranded DNAs at
single-copy genomic loci in mammalian cells, with induced recombination frequencies of
up to 0.11%. The TFO-induced recombination was shown to be sequence-specific based
on comparisons of both mismatched oligonucleotides and mismatched chromosomal
target sites. A TFO dose-dependence was seen in two sets o f experiments, including one
in which the total amount of transfected nucleic acid was held constant. Comparisons of
sense and antisense orientation donor DNAs indicated a preference for antisense donors
regardless o f the orientation of the triplex, and a comparison o f donor DNA length
showed that the 5 1-mer was more active than either the 30-mer or the 69-mer,
This work was facilitated by a sensitive Flue gene assay capable of reporting
recombination events at frequencies over a wide range, from below 0 .0 1 % to

1 0 0

%.

Based on a consistent linear relationship between luciferase activity in cell lysates and the
percentage o f wild-type cells in mixed cell populations (as established using two separate
sets o f matched cell lines), the assay allows for straightforward calculation of
recombination frequencies from enzyme activity. The use o f the CHO-Flp parental cell
line for site-specific introduction o f the Flue gene cassettes also provided an additional
ability to compare TFO-induced recombination in different sequence contexts (and with
both purine and pyrimidine TFOs) but still at the same chromosomal locus in otherwise
isogenic cells.
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The similar results in the two cell lines with two different types o f TFOs provide
further evidence for the fundamental ability o f triple helix formation to create DNA
helical distortions that can induce recombinagenic repair events in cells. O f note, there
were no differences between parallel and anti-parallel binding TFOs vis a vis their ability
to stimulate recombination. This is in contrast to the distinct effects seen when we
compare donors homologous to the sense versus antisense strands o f the target duplex.
Flence, it is likely the extent o f helical distortion created by the triplex, not its polarity,
that confers the ability to stimulate recombination.
Compared to the amidate-modified TFO, LNA, 2'AE, and pdU-modified TFOs
did not induce significant recombination in the genomic target. The pdU result was
surprising as it induced recombination in the episomal target. The bulky base may be less
effective in the single-copy chromosomal target compared to the episomal target. Several
new chemistries not explored in Chapter 2 were also tested in this genomic target. The
DEED analogue used in Chapter 2 showed poor binding likely due to the chirality o f the
phosphorus atom o f the phosphoramidate intemucleoside linkages [36, 37], The use o f a
non-natural a anomery instead was proposed to offset this problem. Unlike their P
analogues, and despite the chirality of the phosphorus atom, these molecules hybridize
tightly to their DNA targets in an anti-parallel fashion at neutral pFl and without MgCU
[38]. Between the aDEED TFO, the PDMAP TFO, and the aDMAP TFO, the aDEED
TFO showed the greatest induction o f recombination but that effect was still significantly
less than that o f amidatel 8 . This may have been due to decreased binding to this target
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site or due to decreased delivery. Twisted Intercalating Nucleic Acids (TINA) linkages
as part o f the backbone structure o f the TFO [39] were also tested and none o f the TINA
oligonucleotides induced recombination significantly or repressed wild-type expression.
The cellular effect of the TINA TFOs has not yet been determined. The TINA TFOs may
influence intracellular binding or influence repair/recombination/damage recognition
pathways. Binding o f the DMAP and DEED TFOs and the TINA TFOs to the duplex
used in Chapter 2 was not tested.
The CPT TFOs used in this work showed inhibition o f an episomal target in FleLa
cells [40, 41]. CPT TFOs can recruit topoisomerase I in a sequence-specific manner and
induce stable cleavage complexes in cell nuclei [42]. CPT TFOs can inhibit transcription
o f an episomal target only when a cleavage site is present near the TFO end [42].
Topoisomerase II inhibitor conjugated TFOs form stable triplexes in vitro [43], but no in
vivo activity o f these complexes has been detected. The CPT-modified TFO induced
recombination at low levels in cell lines containing the Flue target mutated at two
different distances from the TBS. No induction o f recombination was seen with the other
CPT TFOs. Repression of wild-type Flue observed with the camptothecin
oligonucleotide was similar to that seen with the controls.
It was thought that the intercalation of the camptothecin conjugation would create
a structure that slows turnover or inhibits repair or recombination. Thus, CPT TFOs
might create a camptothecin conjugate that blocks topoisomerase I which leads to a
persistent strand break and therefore a higher likelihood o f recombination. In fact, we
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found the opposite; there was a substantial reduction o f recombination, suggesting that a
structure was created that the cell could not resolve. Perhaps merging the amidate
modification with either the TINA or the CPT modifications would augment the
effectiveness of induction o f recombination in this or other genomic targets.
The ability of triplex formation to induce repair has been shown to depend on the
nucleotide excision repair (NER) pathway. In a study using human cell-free extracts,
TFO-induced intermolecular recombination was blocked by depletion o f the NER
damage recognition factor, xeroderma pigmentosum group A (XPA) protein, and was
restored by supplementation o f the depleted extracts with purified XPA protein [44],
Similarly, TFO-induced recombination in an episomal target was absent in human mutant
cells deficient in XPA but was restored by complementation o f the mutant cells by
expression of XPA cDNA [45], Hence, TFOs exert an effect on recombination by
engaging the cellular repair machinery to generate recombinagenic intermediates. Initial
studies demonstrated that DNA strand breaks are produced in the repair o f triplex
structures, but the exact pattern o f repair-related incisions has not yet been mapped [5].
In a sense, the action o f TFOs through cellular DNA repair pathways is conceptually
similar to the action o f exogenous small interfering RNAs through the cellular RNA
processing pathways.
Recent reports o f the ability of ZFNs to induce recombination further demonstrate
the concept that the generation of site-specific DNA damage is recombinagenic. ZFNs
and TFOs represent related approaches, in that both are major groove binding molecules
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that can create site-specific DNA damage to stimulate recombination. ZFNs do this via
the cleavage activity of the fused endonuclease domain. TFOs do this by forming triple
helices, which are recognized by repair factors, leading to repair-associated strand breaks
and thereby activating the target site for recombination. However, TFOs are chemically
synthesized and obviate the need for expression constructs. The general toxicity and
safety profile o f oligonucleotides has been extensively studied, and specific
oligonucleotides have already been approved for therapeutic use in humans [46], In
contrast, there are data suggesting that ZFNs can be toxic to cells when highly expressed
[14], presumably due to off-target nuclease activity that is not completely regulated by
the zinc finger domain.
Although TFOs were shown here to induce intermolecular recombination at
chromosomal sites by short single-stranded DNAs, they may also be effective in
combination with other DNA molecules, including long single- or double-stranded DNAs
and even viral vector genomes, such as AAV. In the case o f AAV vectors, it has already
been demonstrated that INceZ-induced DSBs can stimulate increases in AAV-mediated
recombination rates [47], Hence, TFO technology may prove to be complementary to a
number of other approaches that are being developed to mediate gene correction in
mammalian cells.
Although TFOs have been shown to induce site-directed sequence changes at
chromosomal loci in cells in culture and even in mice following systemic administration,
improvements are still needed in the efficiency o f gene targeting by TFOs. The
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frequencies o f up to 0.1% obtained in this work represent up to 9-fold better than what
can be achieved by transfection o f the donor DNA fragments alone under the same
conditions. However, efforts to improve intracellular binding properties o f TFOs and to
promote intra-nuclear TFO delivery will be needed to achieve the desired gains in
efficiency. Nonetheless, the work reported here constitutes an important next step and
establishes the ability o f TFOs to stimulate the site-directed recombination at
chromosomal loci in mammalian cells.

325

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

J. M. Kalish
The majority o f this work is currently accepted for publication in the journal Molecular
Therapy with M.P. Knauert and J.M. Kalish as co-first authors. The luciferase
chromosomal target was designed by and the CHO-R13 and CHO-RWT cell lines were
made by Melissa Knauert. The AG30 data was collected with the help of Denise Hegan.
All other cell lines were made by and data collection was done by J.M. Kalish.
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Figure 1A and B. Schematics of single-copy chromosomal targets. (A) Schematic of
the luciferase reporter gene cassettes in the CHO-R13 and CHO-Y13 CHO cell lines used
in this work. The sequences and positions o f the TFO binding sites (TBS) relative to the
stop codon mutations in the Flue coding regions are shown with the distance from the
start o f the TBS to the mutation-to-be-corrected indicated below each construct. The
mutant Flue genes both contain a stop codon mutation 13 bp downstream from the start
of the coding region, as indicated by the inverted triangle (y ) . The TFOs, AG30 and
am idatel 8 , bind to their respective duplex target sites in the orientations shown; duplex
TBS orientation is as indicated by the 5' and 3' labels. (B) Schematic o f TFO-induced
recombination and gene correction, with TFO binding to the TBS and alignment of
single-stranded donor DNAs with the homologous target sequences, as indicated.
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Figure 1C. Development of standard mixing curves. Graph o f the relationship
between the percent Flue wild-type cells among Flucl3 mutant cells in mixed cell
populations and the luciferase activity in the lysates of the mixed populations as
measured by RLUs per pg protein. Mixed cell populations were established with the
indicated proportions o f Flue wild-type cells among Flucl3 mutant cells to establish a
standard curve. CHO-YWT w/ CHO-Y13 indicates the curve determined by mixing Flue
wild-type cells containing the Flue target with the A-rich (T C I 8 ) TFO binding site and
the corresponding Flue 13 mutant cells. CHO-RWT w/ CHO-R13 refers to the curve
determined by a similar analysis o f mixed populations o f Flue wild-type cells containing
the G-rich (AG30) TFO target site and the corresponding F lucl3 mutant cells. Six
replicates were performed per data point, and error bars indicate one standard error above
and below the experimental mean.
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Figure 2. TFO-induced recombination at a single-copy chromosomal target. (A)
Recombination in CHO-R13 cells induced by the matched sequence-specific TFO,
AG30. Cells with the indicated TFO binding sites (CHO-R13: G-rich purine m otif TBS
matched to AG30; CFIO-Y13: A-rich pyrimidine m otif TBS matched to am idatel 8 ;
CFIO-YScr: A-rich pyrimidine m otif TBS mismatched relative to am idatel 8 ) were
transfected with either donor alone (no TFO), donor plus AG30 (specific for the G-rich
target site) or donor plus 12AG30 (scrambled sequence G-rich oligomer mismatched at
12 bp versus the target in the CHO-R13 cells); cell lines are indicated by their suffix
(R13, Y13 and YScr for CHO-R13, CHO-Y13, and CHO-YScr cells, respectively).
Donor alone sample indicates CHO-R13 cells transfected with 0.2 pg/well o f as51; all
other samples received 0.2 pg as51 and 0.2 pg o f the TFO or control oligonucleotide, as
indicated. Gene correction to produce functional luciferase genes was detected by
analysis of luciferase enzyme activity in the lysates o f the treated cells. Results are
presented as fold induction over donor alone (ssDNA 51-mer, as51) on the right axis and
calculated percent recombination on the left axis. 12AG indicates 12AG30 as described
in materials and methods; all other TFOs are indicated by their full designation as
described in materials and methods. The frequencies o f induced recombination were
determined based on RLU/protein measurements and reference to the standard curves in
Fig. 1C. At least six replicates were performed for each sample, and error bars indicate
one standard error above the experimental mean. (B) Recombination in CF10-Y13 cells
induced by the specific TFO, amidatel 8 . Conditions and cell lines are as in (A); LNA
indicates LNA18 as described in materials and methods.
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Figure 3. Dose dependence of TFO-induced recombination. (A) Dose dependence o f
induced recombination by the G-rich TFO, AG30. CHO-R13 cells were treated with 0.2
pg/well o f as51 donor and increasing amounts o f AG30, as indicated. Fold induction o f
recombination over donor alone samples is noted on the left axis and recombination
frequency is presented on the right axis. The frequencies o f induced recombination were
determined based on RLU/protein measurements and reference to the standard curves in
Fig. 1C; at least six replicates were performed for each sample, and error bars indicate
one standard error above the experimental mean. (B) Dose-dependence of induced
recombination by the T-rich TFO, am idatel 8 . CHO-Y13 cells were treated with 0.2
pg/well of as51 donor and increasing amounts o f amidate 18 (amidate), as indicated.
Results are presented as in (A). (C) Triplex-induced recombination in CHO-R13 cells as
a function o f TFO dose in samples transfected with a fixed total amount o f nucleic acids
(sum o f TFO and donor DNAs). In each sample, CHO-R13 cells were treated with 0.6
pg total nucleic acid/well. Concentrations o f as51 and AG30 were adjusted inversely as
indicated. Results are presented as in (A). (D) Triplex-induced recombination in CHOY13 cells as a function o f amidate 18 (amid) dose in samples transfected with a fixed total
amount o f nucleic acids (sum o f TFO and donor DNAs), as above (A).
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Figure 4. The effect of donor DNA orientation on recombination. (A) Luciferase
gene correction by co-tranfection o f either sense or antisense single-stranded donor
DNAs and the TFO, AG30. CHO-R13 cell lines were treated with 0.2 pg o f either sense
or antisense 51-mer DNAs with (+) or without (-) 0.2 pg o f AG30, as indicated. (B)
Luciferase gene correction by co-tranfection o f either sense or antisense single-stranded
donor DNAs and the TFO, am idatel 8 . CHO-Y13 cell lines were treated with 0.2 gg of
either sense or antisense 51-mer donor DNAs with (+) or without (-) 0.2 gg o f am idatel 8
(amid). All results (A and B) are presented as fold increase in recombination over as51
donor alone. The frequencies o f induced recombination were determined based on
RLU/protein measurements and reference to the standard curves in Fig. 1C; at least six
replicates were performed for each sample, and error bars indicate one standard error
above the experimental mean.
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Figure 5. The effect of donor length and modification on recombination. (A)
Influence o f the length o f the single-stranded donor DNAs. CHO-Y13 cells were treated
with 25 nM o f antisense, phosphorothioate end-modified donor DNAs with (+) or
without (-) 0.2 pg o f am idatel 8 . Single-stranded donor DNAs tested were o f length 30
nt, 51 nt and 69 nt. (B) Length comparison o f LNA donors. CHO-Y13 cells were treated
with 25 nM of antisense, LNA end-modified donor DNAs with (+) or without (-) 0.2 pg
o f am idatel 8 . (C) LNA versus phosphorothioate donors. A fixed amount (25 nM) o f
donor (either as30 or LNA30 as labeled) was added to each well o f CHO-Y13 cells.
Doses o f amidate 18 as labeled were added. All results (A, B, and C) are presented as
fold increase in recombination over as51 donor alone. The frequencies o f induced
recombination were determined based on RLU/protein measurements and reference to the
standard curves in Fig. 1C; at least six replicates were performed for each sample, and
error bars indicate one standard error above the experimental mean.

338

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

J. M. Kalish
CH0 -Y13

A

0.08
o
Q
<5
o>

0.06

35

0.02

oo

0.04

o

LL

0.00
<
z

TFO

B

CHO-Y13

10.0

0.09

7.5

'

5.0

0.06

2.5

0.03

0.00

0.0
TFO

co

TS

Q.

<
<
5 sQ
Q
b
CCL

Q
UJ
UJ
Q
a

Figure 6. A comparison of chemically modified pyrimidine m otif TFOs. (A) A
number of chemically modified TFOs in the pyrimidine m otif were compared.
A m idatel 8 (amid), 2'-0-(2-aminoethyl)-ribose (2'-AE), 5-(l-propynyl)-2'-deoxyuridine
(pdU), and (R)-l-0-[4-(l-pyrenylethynl)phenylmethyl]glycerol, Twisted Intercalating
Nucleic Acid (TINA)-modified TFOs were compared in CF10-Y13 cells. TFOs are as
described in materials and methods above or in Chapter 2. (B) A comparison of
phosphoramidate modified-TFOs. N, N-dimethylaminopropyl-phosphoramidate
(aDMAP and (3DMAP) and N, N- diethylethylenediamine (aDEED) modified TFOs were
compared with amidate 18 for induction o f recombination in CEIO-Y13 cells, using
electroporation for delivery o f the TFO. as51 was used as the donor at 0.2 pg/well and
TFOs were added at 2 pM, except for amidate 18 which was added at 0.5 pM. TFOs are
as described in materials and methods above. All results (A and B) are presented as fold
increase in recombination over as51 donor alone. The frequencies o f induced
recombination were determined based on RLU/protein measurements and reference to the
standard curves in Fig. 1C; at least six replicates were performed for each sample, and
error bars indicate one standard error above the experimental mean.
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Figure 7. C am ptothecin conjugated TFO s. (A) TUCL4CPT (CPT) induction o f
recombination in CHO-YScr cells. The dose effect o f the CPT-conjugated TFO was
demonstrated for cells with a mutation 13 bp from the ATG start site o f Flue. as51 at 0.2
pg/well was used as the donor. (B) TUCL4CPT induction o f recombination in CHOYScr202 cells. A 51-mer antisense ssDNA homologous to the wild-type Flue sequence
and flanking the 202 bp mutation was used at 0.2 pg/well. The dose effect o f the CPTconjugated TFO was demonstrated for cells with a mutation 202 bp from the ATG start
site o f Flue. C. Repression o f Flue by CPT TFOs. The ability o f CPT TFOs to repress
wild-type Flue was tested in CHO-YWT cells as compared to a phenyl-conjugated TFO,
TUCL4Ph2 (Ph2) and an unconjugated TFO, TUCL4NH2 (NH2). TFOs were each
added at 0.2 pg/well. Results (A and B) are presented as fold increase in recombination
over as51 donor alone. The frequencies o f induced recombination were determined
based on RLU/protein measurements and reference to the standard curves in Fig. 1C; at
least six replicates were performed for each sample, and error bars indicate one standard
error above the experimental mean. Result C is presented as fraction and percent o f wildtype Flue activity as compared to untreated wild-type Flue cells.
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Introduction
Mammalian cells rely on the N ER pathway to remove bulky DNA helixdistorting lesions (such as pyrimidine dimers) [1]. Unrepaired lesions lead to mutations
or cell death; thereby NER serves (in conjunction with other repair pathways) to maintain
genomic integrity. Deficiency in NER is responsible for the three rare autosomal
recessive diseases, xeroderma pigmentosa (XP), Cockayne syndrome (CS), and the
photosensitive form o f trichothiodystropy (TTD) [2], XP patients exhibit extreme
ultraviolet radiation (UV) sensitivity and increased incidents o f sunlight-induced cancers
[2]. XP has been classified into 7 complementation groups, XPA through XPG [2], Each
group lacks or has a protein deficient in part o f the NER complex.
NER involves damage recognition and incision, excision o f the damage, repair
resynthesis, and ligation [3] (Appendix 2). The NER reaction has been reconstituted in
vitro [4-6] and the role o f most o f the factors involved is known, but the order of
recognition and associated binding is still the subject o f debate. Within the NER pathway
there are two different sub-pathways based on the transcription status o f the DNA
containing the lesion, transcription coupled repair (TC-NER) and global genome repair
(GGR) [3]. These pathways differ in their recognition but have a common incision
process. Dual incisions are made 5-6 nucleotides 3' and 22-24 nucleotides 5' to thymine
dimers in mammalian cell-free extracts with excision products 27-32 nucleotides long [7,
8

]. The location o f the incisions has been shown to vary with the type o f lesion to be

repaired [5], XPG makes the 3' incision and XPF-ERCC1 makes the 5' incision [9]. In
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repair o f a cisplatin lesion, Evans et al. demonstrated that an open complex forms that is
dependent on the core NER factors (all but XPF-ERCC1) and the incisions occur near the
junctions o f this open bubble with dsDNA [10]. Cross-link repair may require sequential
excisions and repair on both strands and/or intra-strand recombination [11-13]. The
location of the dual incisions in repair o f a triplex is not known and would be essential in
uncovering the mechanism o f triplex repair.
Previous work in the Glazer lab demonstrated that triplex-induced mutagenesis
and recombination is dependent on the nucleotide excision repair (NER) pathway [1417]. Triplex-induced repair and recombination requires XPA, a NER recognition factor
[16, 18, 19]. A 10 nucleotide TFO, conjugated to psoralen, and mono-adducted to duplex
DNA produces excision products while a 30 nucleotide TFO does not produce excision
products [20]. The gene modification activity o f the 30-mer TFO, despite the lack of
excision products suggests that multiple repair pathways may function in triplex repair.
This idea is also consistent with the fact that the length of attachment o f some TFOs (i.e.
TFOs 30 nucleotides long) exceeds the canonical excision span o f NER.
The mechanism of triplex repair is not currently understood and these
experiments are designed to illuminate aspects o f this mechanism. To understand the
mechanism o f triplex action and to elucidate the pathway by which triplexes promote
repair and recombination, the incision step o f the bulky adduct created by triplex binding
needs to be mapped. The nature o f these excision products and the location o f the
incisions have not been previously evaluated, and those are the goals o f this work. In
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order to ultimately develop an assay to locate the sites o f incision made in repair o f a
TFO bound to duplex DNA, strides were taken to create substrates with altered helical
structures to address this question.
In order to determine the biochemical nature o f the excision o f a triplex structure
from DNA, a number o f factors need to be considered. First, the repair pathways
involved include at least NER, but given that NER alone cannot excise a 30-mer TFO
bound to duplex DNA, other repair pathways are likely to be active as well. Second, in
order to understand the biochemical mechanism o f the incisions, the excision products
themselves need to be visualized and deciphered. Finally, the complexity o f these
incisions and the alteration of incisions based on different altered helical structures by
different TFOs need to be addressed. In the work presented in previous chapters, repair
o f pyrimidine m otif triplexes was shown to be dependent on NER (as has been previously
demonstrated for purine m otif triplexes). Additionally, binding affinity alone is not
sufficient for induction o f repair and recombination. Chemical modifications that are
more helically distorting are more inducing of repair and thereby more inducing o f
recombination. In attempting to capture excision products, a variety o f techniques have
been attempted as outlined here, and while some have been more productive than others,
they demonstrate that there is at least one incision occurring in repair o f 15-mer and 24mer TFOs.
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Materials and Methods

Oligon ucleotides
pso-AG30, pso-5'AGGAAGGGGG GGGTGGTGGG GGAGGGGGAG3’; psoNewlO, 5'pso-AGGAAGGGGG3'; pso-N ew l4, 5'pso-AGGAAGGGGG AGGG3'; psoNew23, 5'pso-AGGAAGGGGG AGGGAGGGGA GGG3'; and pso-New29, 5’psoAGGAAGGGGG AGGGAGGGGA GGGAGGGGG3 1 were synthesized by Oligos, Etc.
32

psoNewl 1, psoNew l5, psoNew24, and psoNew30 were created by adding [a- P]ddA
(Amersham Biosciences) to the 3'-end o f psoNewlO, psoN ew l4, psoNew23, and
psoNew29 as described below. IC1, 5'GGGACCTGAA CACGTACGAA
ATTCGATATC CTCTAGCCAG ATCTGCGCCA GC3'; IC2, 5 'T G AGGGGG AG
GGGGTGGTGG GGGGGGAAGG ATC3'; IC3, 5'TTGGGCTGCA GCAGGTAGAC
TCTAGAGGAT CACGAGCGAA CTCTAATGCA CC3'; IC4, 5'CAGATCTGGC
TAGAGGATAT CGAATTTCGT ACGTGTTCAG GTC3'; IC5, 5’TGCAGCCCAA
GATCCTTCCC CCCCCACCAC CCCCTCCCCC TCAGCTGGCG3'; IC 6 ,
5'TTGGTGCATT AGAGTTCGCT CGTGATCCTC TAGAGTCTAC CTGC31; N ew l 1,
5'AGGAAGGGGG A3'; N ew l3, 5'AGGAAGGGGG AGG3’; N ew l5,
5'AGGAAGGGGG AGGGA3'; New20, 5'AGGAAGGGGG AGGGAGGGGA3';
New24, 5'AGGAAGGGGG AGGGAGGGGA GGGA3'; New30, 5'AGGAAGGGGG
AGGGAGGGGA GGGAG GGGGA3'; NEWPUR, 5'GGTACCGAAT TTCGGCCAGG
GGGAGGGAGG GGAGGGAGGG GGAAGGATTC GAACCTT3'; and NEWPYR,
5

'AAGGTTCGAA TCCTTCCCCC TCCCTCCCCT CCCTCCCCCT GGCCGAAATT
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CGGTACC3' were synthesized by W.M. Keck Foundation Biotechnology Resource
Laboratory (Yale University). N ew l 1, N ew l5, New24, and New30 are of the same
sequence as psoNewl 1, psoNew l5, psoNew24, and psoNew30, described above without
the psoralen on the 5'-end and the [a- P] ddA on the 3'-end.
CHO cell-free extracts
CHO cells were harvested from forty 15 cm dishes and centrifuged at 3000 rpm
for 10 minutes at 4°C. Cells were washed twice with 10 times packed cell volume (PCV)
o f cold PBS, resuspended in 4 PCVs o f 10 mM Tris-HCl pH 7.5, 1 mM EDTA, and 5
mM DTT, and incubated on ice for 20 minutes. Resuspended cells were homogenized
and 4 PCVs o f cold 50 mM Tris-HCl pH 7.5, 10 mM M gCh, 2 mM DTT, 25% sucrose,
and 50% glycerol were added. 1 PCV o f saturated ammonium sulfate (4.2 M, pH 7.2)
was added drop wise and stirred for 30 minutes, following the last drop, at 4°C. The
sample was then centrifuged at 45000 rpm in Ti70 rotor for 3 hours at 4°C. The
supernatant was collected and the volume was measured, and 0.33 g o f ammonium
sulfate per mL o f supernatant was added slowly. Then 100 pL 1 M NaOH/10 g
ammonium sulfate was added and stirred for 30 minutes at 4°C. The sample was then
centrifuged at 12000 rpm in a SS34 rotor for 30 minutes at 4°C. The pellet was
resuspended in dialysis buffer (25 mM HEPES-KOH, pH 7.9, 100 mM KC1, 12 mM
MgCb, 0.5 mM EDTA, 2 mM DTT, 15% glycerol) using 1/20 pellet volume of the
supernatant and dialyzed at 4°C for 3 hours followed by another 3 hours with fresh
dialysis buffer. The dialysate was centrifuged at 14000 rpm in Eppendorf tubes in a
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microcentrifuge for 20 minutes at 4°C. This protocol was kindly given to us by
Tadayoshi Bessho. Aliquots o f 100 pL were made and frozen in liquid nitrogen. Protein
concentrations were measured by Bradford assay [21].
Linear substrates
pNEWAG and pNEWTC were constructed from pIND/lacZ (Invitrogen) by
cloning into the BamHI restriction site following the annealing o f ssDNAs,
5'GCAGAAAGCG GATCCTTCCC CCTCCCTCCC CTCCCTCCCC CTAGAGACTT
GTTCG3' and 5'CGAACAAGCT TCTAGGGGGA GGGAGGGGAG GGAGGGGGAA
GGATCCGAAG CTTTCTGC3' that were synthesized by W.M. Keck Foundation
Biotechnology Resource Laboratory (Yale University). The distinction between
pNEWAG and pNEWTC is the orientation o f the TBS. A 195 bp fragment was cut out
o f these plasmids with Kpnl and XmnI, gel purified, and when not used in conjunction
with end-labeled TFOs these substrates were 5'-end-labeled with [y- P]ATP (Amersham
Biosciences). Following phenol-chloroform extraction, TFOs were bound to this
substrate and following mono-adduct formation, subjected to the incision reaction, as
described below. Alternatively, one o f two 57mers was end-labeled and annealed with its
unlabeled complement.
End-labeled TFOs
TFOs (pso-NewlO, pso-N ew l4, psoNew23, and pso-New29) were designed with
psoralen on the 5'-end so that [a- P]ddA could be added to the 3'-end to complete the
oligonucleotides (pso-Newl 1, pso-N ew l5, pso-New24, and pso-New30). [a- 3 2 P]ddA
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was added via terminal transferase (New England Biolabs) per manufacturer instructions.
The synthesized sequences were as shown above and the final sequences were psoN ewl 1, 5'pso-AGGAAGGGGG A3'; pso-N w l5, 5'pso-AGGAAGGGGG AGGGA3'; and
pso-New24, 5'pso-AGGAAGGGGG AGGGAGGGGA GGGA3'; pso-New30, 5’psoAGGAAGGGGG AGGGAGGGGA GGGAGGGGGA3'. In vitro binding and monoadduct formation were done as described below. Samples were concentrated in
microconlOOs (Millipore), incision was as described below, then 10 pL o f 2.5x
formamide dye was added, samples were boiled for 5 minutes and loaded onto 15%
polyacrylamide gels.
Internally labeled substrates
A double stranded 137 bp fragment was also built from

6

ssDNAs (IC1-IC6 as

described above). One o f the six ssDNAs was 5'-end-labeled with T4 kinase and
[y-3 2 P]ATP prior to construction and the remaining 5 ssDNAs were kinased together.
The ssDNAs were mixed, phenol-chloroform extracted, ethanol precipitated, and
resuspended in DNA dilution buffer (Roche, Rapid ligation kit). The sample was heated
to 65°C for 10 minutes and then cooled at 23°C, for 20 minutes, then ligation buffer and
ligase were added. Samples were incubated at 23°C for 2 hours and then for 18 hours at
4°C. Gel purification was as described below followed by in vitro binding as below.
Plasmid substrates
psupFGl, a plasmid containing the AG30 TBS sites was used as a plasmid
substrate. In vitro binding was done as described below with psupFGl and pso-AG30
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followed by mono-adduct formation as described below. After the incision reaction
described below, samples were resuspended in water and restriction enzyme cuts

2 0 0

bp

apart were made and the fragments were separated on a 12% polyacrylamide gel. DNA
32

was transferred to a membrane and probed with oligonucleotides labeled with [a- P]CTP
(Amersham Biosciences). The probes were designed to contain all or part o f the AG30
TBS. An internally labeled plasmid was created by cutting pMM2 [22] with BamHI (a
T9
cut at the end o f the TBS), end-labeled with [y- P] ATP, religated, and then used as the
plasmid substrate for TFO binding and incision. In vitro binding, mono-adduct
formation, and the incision reaction were as below. Following the incision reaction, stop
reaction, phenol/chloroform extraction, and ethanol precipitation, a restriction digest was
done as above.
In vitro binding
For linear substrates, 5 jug substrate and 10 //M TFO were used. For plasmids, in
vitro binding was with 3 jug plasmid and 10 //M TFO. In all cases, binding was
performed in 10 mM Tris (pH 7.6), 10 mM MgCB, 1 mM spermine, and 50% glycerol at
37°C for 16 hours.
Third-strand binding assays
Third-strand binding was measured using gel mobility shift assays under native
conditions. Two complementary 30-mers (NEWPUR, NEWPYR) containing the NEW
TBS target were synthesized. Duplex DNA was prepared by mixing 1000 pmol o f each
57-mer together with 50 mM NaCl, incubating at 85°C for 20 minutes, and cooling to
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room temperature before end-labeling with T4 polynucleotide kinase (New England
BioLabs) and [y-3 2 P]ATP. Duplex was gel purified, electroeluted, and filtered by
o

centricon3 (Millipore). A fixed concentration o f duplex at 5 x 10" M was added to
binding reactions with increasing concentrations o f oligonucleotides in

2 0

pi containing

10 mM Tris (pH 7.6), 10 mM MgCE, and 1 mM spermine. Samples were incubated at
37°C for 16 hours and were loaded onto 15% polyacrylamide gels
[acrylamide/bisacrylamide (19:1)] containing 17.8 mM Tris and 17.8 mM boric acid (pH
7.6) and 10 mM M gCh and the gels were run in the same concentration o f Tris-boric acid
and M gC f at 60 V for

6

hours at 23 °C.

Mono-adduct form ation
To establish optimum mono-adduct formation and minimum cross-link formation,
a range of times from 10 seconds to

6

minutes at 320 nm were evaluated. TFOs were

bound to the 57-mer duplex, UVA treated for the indicated time, and visualized on a 15%
polyacrylamide denaturing gel. Ten seconds at 320 nm was used for most o f this work.
Removal o f unbound and unadducted TFO
To dissociate unadducted TFO following mono-adduct formation, 10 mM Tris
(pH 8 ), 1 mM EDTA, and 100 mM KC1 were added to the binding reaction and incubated
for 2 hours at 60°C. Samples were cooled to 23 °C and concentrated in microconlOOs,
rinsed with water, and then incision reactions were performed as below.

4.10

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

J. M. Kalish

Gel purification o f substrates with mono-adducted TFOs
Prior to incision, TFO mono-adducted substrate was resolved on 10% denaturing
gels and the DNA o f the correct size was electroeluted from the gel in lx TBE for two
hours at 15 mA, spun in a centricon30 (Millipore), concentrated in a microcon3
(Millipore), washed with water, and subjected to the incision reaction.
Incision assay
The incision reaction consisted of, lOx repair buffer (0.3 M HEPES-KOH (pH
7.9), 0.4 mM KC1, 32 mM MgCl2, 2 mM DTT, 1 mM EDTA (pH 8 )), 100 mM ATP, 10
mg/mL BSA, 250 ng DNA substrate, and 100 jug o f CHO cell-free extracts. Incision
reactions were incubated for 1 hour at 32°C. Reactions were stopped by adding 1 pL o f
10% SDS and 1 pL o f 20mg/mL proteinase K (Sigma) and incubating at 37°C for 15
minutes, followed by phenol-chloroform extraction and ethanol precipitation. Glycogen
(Sigma) was added to aid in precipitation o f small DNA fragments. Samples were
resuspended in 2.5x formamide dye solution, analyzed on a 12% polyacrylamide gel run
at 65W for 2 hours. If samples were not previously labeled, DNA was transferred to
membranes as described above. Otherwise gels were dried and analyzed on a
phosphorimager (Storm 860, Molecular Dynamics, Amersham Pharmacia Biotech). This
protocol was given to us by Tadayoshi Bessho.
Size standards
To monitor unbound TFO and for smaller size standards N ew l 1, N ew l3, N ew l5,
New20, New24, New30 were 5'-end-labeled via T4 kinase with [y-3 2 P]ATP.
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Results
Altered helical substrates
The initial substrate to be used is a 195 bp duplex (either NEWAG or NEWTC)
with a 3'-end-labeled TFO with a 5'-psoralen bound and mono-adducted just 5' o f the
TFO binding site (TBS) on the purine strand o f the duplex (Fig. 1A). Also explored in
this work are 195 bp duplexes (NEWAG and NEWTC) that are 5'-end-labeled followed
by TFO binding and mono-adduct formation (Fig. IB). Lastly, internally labeled
duplexes are formed through ligation o f 6 ssDNAs, one o f which is 5'-end-labeled prior
to ligation (Fig. 1C). IC2 is labeled in Fig. ICi, IC3 in Fig. ICii, and IC 6 in Fig.ICiii.
Incision activity o f CHO cell-free extracts
In order to ensure excision activity o f the cell-free extracts and our ability to
detect the excision products, a 6-4 photo-adduct containing an internal radiolabel (a kind
gift from Tadayoshi Bessho) was used. Excision o f this 6-4 photoproduct was performed
with extracts we made and the canonical excision pattern was seen (Fig. 2). The excision
products ranging from 24 to 27 nucleotides in length with the primary product being 27
nucleotides were seen only in the presence o f active cell-free extracts and were absent in
the mock reaction without extracts. The amount o f excision products was as expected for
this substrate.
In vitro binding o f 3'-end-labeled TFOs
The initial substrate for incision was a linear 195 bp fragment in conjunction with
a series of 3'-end-labeled TFOs in the purine motif. To 3'-end-label the TFO,
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dideoxyadenine was the only available P

T9

labeled dideoxynucleotide, therefore the

purine TFO sequence had to be redesigned to have an adenine in the appropriate places to
allow for comparison o f different length TFOs 3'-end-labeled with [a- 3 2 P]ddA. Binding
studies were done with these TFOs at pFI 7.6 with 10 mM MgCE and 1 mM spermine to
a 57-mer duplex substrate made o f NEWPUR/NEWPYR. The dissociation constant (Kj),
the molar concentration of TFO where half o f the duplex substrate is bound to the TFO,
was determined for each TFO. N ew l 1 did not have a detectable K<j. N ew l5, New20,
New24, and New30 had Ka’s o f 10"9, 10'8, 10'8, 10' 9 M, respectively (Fig. 3). To create
the appropriate TFO target for these TFOs, their TBS site was cloned into pIND/lacZ in
both orientations. The linear substrates, NEW AG and NEWTC were cut out o f this
plasmid with XmnI and Kpnl creating a 195 bp linear fragment. NEWAG had the purine
strand o f the TBS 5' to 3' and NEWTC had the pyrimidine strand 5' to 3' in the plasmid.
Mono-adduct form ation fo r incision substrates
Psoralen TFOs were chosen because cross-linking or mono-adducting psoralen to
the plasmid substrate provided a greater likelihood o f the TFO being present during the
incision reaction in cell-free extracts. Given our interest in the TFO being adducted to
the strand to which the TFO is bound and not to both strands o f the duplex, the efficiency
of mono-adduct formation with a given substrate needed to be determined. While
previous work in the Glazer lab showed 12 minutes at 447 nm was optimum for monoadduct formation and

6

minutes at 320 nm was optimum for cross-link formation [23],

with these substrates and the psoNew TFOs 10 seconds at 320 nm proved optimum for
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mono-adduct formation (Fig. 4). These results are for the pso-NewlO TFO and are
representative o f the other pso-New TFOs used in this work. Lanes 1, 3, 5, 7, and 9
contain labeled duplex alone without TFO. Lanes 2, 4, 6 , 8 , and 10 contain labeled
duplex bound to TFO prior to exposure to UVA. The lanes without TFO did not show
any mono-adduct or cross-link formation. Given that this is a denaturing gel, only monoadducted or cross-linked structures, which are both larger than the duplex, will move
more slowly through the gel matrix. A TFO mono-adducted to one duplex strand is
larger than the strand alone and a TFO cross-linked to both strands o f the duplex is even
larger. The smallest bands (seen in all lanes) represent the duplex while the slightly
larger bands (seen in Lanes 2, 4, 6 , 8 , and 10) indicate mono-adduct formation between
one o f the duplex strands and the TFO. The largest bands (seen in lanes 2, 4, 6 , 8 , and
10) indicate cross-link formation between the TFO and both strands o f the duplex. With
time of UVA exposure increasing, mono-adduct formation decreases and cross-link
formation increases. The optimum mono-adduct formation and minimal cross-link
formation occurs at 10 seconds o f UVA exposure.
Incision with 3'-end-labeled TFOs on linear substrates
Using psoNew24 with NEWAG and NEWTC linear substrates (unlabeled)
binding, mono-adduction, and incision are as above. In Fig. 5, Lanes 1 and 2 show
psoNew24 TFO only. The banding represents the psoNew24 TFO alone with its dimer
and possible G-quartet (as this is a G-rich TFO). Lane 3 shows NEWAG with psoNew24
bound, mono-adducted, and incubated with CHO cell-free extracts. This lane shows a
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small amount o f large intact substrate, a middle size product (G-quartet formation), a
smaller prominent product (unbound TFO), and a smaller ladder o f possible incision
products. Lane 4 shows NEW AG with psoNew24 bound, mono-adducted, and incubated
with all o f the same conditions as Lane 3 except dialysis buffer alone was added in place
o f cell-free extracts. This lane shows more intact substrate, G-quartet formation,
unbound TFO, and less possible incision products. Lanes 5-9 show end-labeled N ew l 1,
New 15, New20, New24, and New30, respectively. Recall that since the TFO carried the
label, only fragments adducted to the TFO or TFO complexes alone are seen. The
resulting image indicated a major product between 19 and 23 nucleotides in length (Fig.
5, Lane 3). This approximate size was determined by comparison to psoNew24 alone
(Lanes 1 and 2) and end-labeled N ew l 1, New 15, New20, New24, and New30 in Lanes
5-9.
The signal distinction between the amount o f this product with and without
extract was small (compare Fig. 5, Lanes 3 and 4) and confounded by the fact that the
labeled TFO ran at about the same size. Therefore, removal o f the unbound TFO was
necessary to confirm that these products were indeed excision fragments and not unbound
TFO. To this end following TFO binding and mono-adduct formation, TFO binding was
disrupted and size filtration was used to remove excess, unbound, and unadducted TFO
[22] (Fig. 6 A). Labeled TFO allows for monitoring o f the removal o f unbound TFO with
size separation columns. Size filtration removed most o f the unbound psoNew24 TFO,
but a ladder similar to that seen in Fig. 5, Lane 3 remained (Fig. 6 B). Gel purification on
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a

1 0

% denaturing gel was also employed and the yield o f large substrate alone (and no

small ladder) is shown in Fig. 6 C.
The products resulting from incision after size purification showed a different
pattern from the pre-purification results (Fig. 7). Lanes 1 and 2 showed the flow-through
from each size filtration wash. Lane 3 shows NEW TC and psoNew24 bound, monoadducted, and incubated with CLIO cell-free extracts. Lane 4 shows the same binding
and adduction, but mock incubation. Lane 5 shows NEWAG and psoNew24 incubated
with cell-free extracts. Lane

6

shows the same substrate with a mock incision reaction.

Lane 7 shows psoNew24 alone. Lanes 8-11 show end-labeled N ew l 5, New 20, New24,
and New30. Note that the lanes with substrate and TFO but without extract (Lanes 4 and
6

) look similar to the flow through lanes (Lanes 1 and 2) for all small products.

However, comparing the large bands in Lane 3 to Lane 4, and Lane 5 to Lane 6 , there is a
product slightly smaller than the initial substrate in both lanes containing extracts (see
arrows). After only size filtration, there were some small fragments o f excision size with
extract present but without extracts the amount o f labeled TFO was still overwhelming
possible fragments (Fig. 7). The presence o f small excision fragments was still
confounded by remaining psoNew24 TFO. However, it appears that there are larger
products (closer in size to the initial substrates) that are present only when cell-free
extracts are present and absent in the mock incision reaction. Given that the expected
products were small, this gel (Fig. 7) was not run far enough to significantly separate the
larger products.
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In order to clarify the nature o f these products and to determine if the small
fragments were excision products or unbound TFO, gel purification on a 10% denaturing
gel was done with the TFO bound and mono-adducted substrate prior to the incision
reaction. The purified substrate was electroeluted out o f the gel and then the triplex
structure was allowed to re-form prior to the incision reaction. In Fig. 8 , Lane 1 shows
NEWAG and psoNew l5, bound, mono-adducted, and incubated with cell-free extracts.
Lane 2 shows the same substrate and TFO, bound, and mono-adducted but mock
incubated. Lane 3 shows NEWAG and psoNew24, bound, mono-adducted, and
incubated with cell-free extracts. Lane 4 shows the same substrate and TFO, bound, and
mono-adducted but mock incubated. Note in both Lanes 1 and 3 there are two products
smaller than the 195 bp substrate and TFO (see arrows), these products are not present in
Lanes 2 and 4 (with the mock incision). Lanes 5 and

6

show the substrates and TFO

without the mock or actual incision reaction. Lanes 7-10 show end-labeled New30,
New24, New20, and N ew l5, respectively. The purified substrate used for incision in
Fig.

8

is visualized in Fig. 6 C.
Following this extra purification step, there was a trace amount of small product,

but there was minimal difference of this product between the incision reaction and the
mock reaction (Fig. 8 , compare Lane 1 to 2 and Lane 3 to 4). The major difference
between the incision reaction products and the mock reaction was seen in the production
of two fragments smaller than the initial substrate but too small to be the excision
fragments that would be expected if a dual incision reaction occurred and the TFO-
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adducted fragment was released. These products suggest that a single incision was made
on one side or the other o f the TFO mono-adducted and bound to the duplex. Since the
TFO was labeled, only the strand adducted to the TFO was detected and the products
visualized in Fig.

8

contain the TFO and some part o f the initial substrate.

Internally labeled substrates
In order to locate the site o f this incision, an internally labeled substrate was
designed. This internally labeled substrate was similar to that used in previous work
studying incision o f thymine dimers [7, 8 ], This internally labeled substrate was built by
ligating

6

ssDNAs together, one o f which was 5'-end-labeled prior to ligation. The

internally labeled duplex was designed to be 137 bp long. The construction o f the duplex
is shown in Fig. 1C. Any one or more o f the ssDNAs can be 5'-end-labeled before
ligation, yielding several possible locations o f a radioactive label on the substrate. The
construction o f these duplexes requires a gel purification step to completely isolate
ligated products and to remove partially ligated products (Fig. 9). Lane 1 shows the 195
bp NEWAG substrate for size comparison. Lane 2 shows radiolabeled IC2 and minimal
partially or fully labeled product. Lane 3 shows radiolabeled IC3 with fully and partially
ligated products and IC3 alone. Lane 4 shows radiolabeled IC 6 with fully and partially
labeled ligation products and IC 6 alone. Lanes 5 and

6

show IC3 and IC 6 alone,

respectively. IC2 was smaller and not visualized on this gel. The IC fragments to
construct this 137 bp duplex ranged in size from 33 nt to 52 nt and several partially
ligated products can be seen in Fig. 9. Fragments o f 85 bp and 94 bp represent partial
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ligations while fragments o f 44 bp and 52 bp represent unligated IC 6 and IC3,
respectively. Very little full size 137 bp substrate is present.
In attempts to increase the yield o f the internally labeled substrate, ratios o f the
ssDNAs and the amount o f labeled ssDNA were varied. Ligation time and the ssDNA
that was labeled were also varied and ssDNAs were gel purified prior to ligation. The
amount o f labeled ssDNA was scaled up markedly to 10 pg in order to increase the
amount of 137 bp product. This substrate was limited in both yield, as the final ligation
product showed a very low yield, and time, as the radioactive signal was time sensitive.
No data was collected with this substrate to date.
Incision with linear end-labeled substrates
All substrates were end-labeled with radioactivity and the binding o f the TFO to
the substrate and mono-adduct formation was verified visually on a denaturing gel.
Therefore the TFO bound state o f the substrate could be verified and the percent o f bound
versus unbound substrate calculated and unbound TFO could be removed if necessary.
Linear substrate duplexes allowed detection o f the fragment between the incision and the
5'-end o f the duplex. The 5'-end-labeled duplex substrate was easy to create in large
quantities by restriction enzyme digestion o f the appropriate plasmid containing the TBS.
With these duplex substrates it was difficult to follow the fragment with the TFO
adducted to it (the potential excision fragment).
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Incision with plasmid substrates
The plasmid substrate psupFGl which contains a TBS for AG30 was used with
pso-AG30 as the TFO. The plasmid substrate required an additional step o f restriction
digestion to cut out a fragment small enough to be visualized on a polyacrylamide gel
(about 200 bp). Additionally, since the plasmid was not internally labeled, the products
were run on a gel, transferred to a membrane, and then probe hybridization was attempted
to analyze the products. Probes to the AG30 target site and surrounding sequence were
used. Although size filtration was used to remove unbound TFO from the sample mix
before the incision reaction was carried out, probes could also bind to the remaining
unbound TFO, and differentiating between excess TFO and incision products was
difficult. Results with this substrate and method were limited and difficult to interpret.
Attempts to use an internally labeled plasmid and a 3'-labeled TFO with a plasmid did not
show positive results, perhaps due to loss o f products in the extra restriction enzyme step
required prior to visualization on a gel.

Discussion
Determining the nature o f the incision products required forming a specific triplex
structure, incubating that structure with the cell-free extracts for the incision reaction to
occur, and then visualizing the products. Each o f these steps had several obstacles to be
overcome in order to create and visualize triplex products. Based on previous work in the
Glazer lab, incisions were thought to be made 3' and 5' o f the TFO when bound to the
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TBS in removal o f a 10-mer TFO [14], potentially analogous to the incision pattern seen
in excision o f a thymine dimer [7, 8 ]. However, a 30-mer TFO (AG30) did not yield a
similar excision product. This led us to speculate that while NER may still make
incisions near the triplex lesion, the “wing-span” o f the NER complex cannot straddle
such a large lesion/helical distortion. However, to test whether or not single or double
incisions do occur, several approaches were considered.
The most promising approach used was a 3'-end-labeled TFO on a linear
substrate, as the fragment bound to TFO could be tracked. The incision products detected
have to be attached to the TFO because only the TFO was labeled. The confounding
signal caused by the unbound TFO could be removed by size filtration and gel
purification. The large size of the products was surprising given that the TFOs used were
a 15-mer and a 24-mer and not a 30-mer. This suggests a different mechanism of
excision compared to repair of a 10-mer. This mechanism may be similar to that for the
30-mer or could represent an entirely different mechanism. Previous notions of incision
of a 10-mer but not a 30-mer were based on repair o f intermediates o f a TFO adducted to
a plasmid [25], While we have shown that these products are smaller than the initial
substrate and represent a fragment adducted to the TFO, the exact location o f the incision
and the nature o f these products remains to be determined.
Labeling the TFO at the 3'-end (as there is psoralen on the 5'-end) allows for the
fragment with the mono-adduction to the TFO to be tracked following incision. This
fragment should be o f a different mobility than the labeled TFO alone, and may have a
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Y-like structure (if the mono-adduct is still intact). This approach also allows for the
direct comparison o f different TFO lengths o f the same sequence. One drawback o f this
approach is that the nature of the excision products will require deciphering a y-shaped
structure and will require synthesis o f a complex ladder o f y-shaped structures of varying
lengths to determine the length o f the excision fragment and the location of the incision.
Additional approaches such as the internally labeled substrate can be used to
decipher these products. The internally labeled substrate offers the advantage of mobility
of the label. And perhaps further increases in the scale o f the ligation can increase the
amount o f the fully ligated product. End-labeling the NEW AG and the NEWTC
substrates instead of labeling the TFOs will allow for determination o f the other products
present in the incision reaction. The end-label approach uses a 195 bp fragment that is
easy to make but the potential, labeled, incision product is a larger fragment representing
the distance from the end of the initial substrate to one incision. Thereby the excised
fragment if there is one, will not be visualized directly. Running samples in parallel with
the TFO labeled in one sample, the substrate labeled in a second sample, and both labeled
in a third sample will help piece together all o f the fragments present after incision.
A complementary approach which has not yet been explored is to monitor
transcription around these incisions to perhaps detect the location at which the incision is
made based on where the polymerase falls off the substrate. This method has been used
to detect peptide nucleic acids bound to a plasmid substrate [24], The concept being that
a disruption in the template could block transcription, whereas in this case either a
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disruption caused by the altered helical structure or incisions made in repair o f this
structure could disrupt transcription and the location of this disruption can be mapped.
Using a plasmid substrate had the advantage o f not introducing radioactivity until
the last step but the disadvantage o f using small fragment probes which bound to
unbound TFO as well. Given that the incisions were likely to be in close proximity to the
TBS, based on data showing that mutation frequencies are highest in the TBS and
specifically near the psoralen mono-adduct or cross-link site [26], probing for the incision
products requires including some o f the TBS in the probe and therefore most probes
binding to the incision products would also bind to free TFO remaining in the sample.
There was no means to visually check this substrate because only the probe was
radioactively labeled, thereby only the fragments adhering to the probe would be
visualized. This approach is appealing because a variety o f probes can be used to map
the resultant excision products. Flowever, these probes are likely to pick up unbound
TFO as well.
Future directions of this work require extensive purification o f the 137 bp
substrate with internal labels. Additionally, end-labeling the 195 bp NEWAG and
NEWTC fragments in order to attempt to detect the same larger products seen in Fig. 5
when the substrate is labeled instead o f the TFO is a priority. Additionally, a similar
repetition with the 137 bp internally labeled fragment would help to further isolate the
location of the incision.
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Once the incision sites for the psoralen mono-adducted TFO pso-New24 is
confirmed by using these other substrates, the other 3'-end-labeled pso-New TFOs should
be used in conjugation with these substrates. A comparison o f the incision patterns
between the different TFOs will suggest the TFO length limitation for the fragment
excision as compared to the single incision. Additionally, TFOs in the pyrimidine m otif
can be evaluated and unconjugated TFOs in both motifs can be compared. Finally,
peptide nucleic acid (PNA)-modified TFOs can be evaluated and compared. In summary,
these techniques allow the location o f incisions in repair o f triplexes to be unveiled and
thereby an important step towards understanding the mechanism o f triplex activity is
made.
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Figure 1. Substrates for incision assay. (A) 3'-end-labeled TFO with psoralen monoadducted to the purine strand o f the TBS on the 195 bp duplex. (B) 195 bp duplex
(NEWAG and NEWTC) 5'-end-labeled with a psoNew TFO bound and mono-adducted.
(C) Internally labeled substrates, i. IC2 fragment was 5'-end-labeled prior to ligation, ii.
IC3 fragment was 5'-end-labeled prior to ligation, iii. IC 6 fragment was 5'-end-labeled
prior to ligation.
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N ew30
excision p ro d u c ts

New13

Figure 2. Verification of CHO cell-free extracts activity and visualization method.
Lanes 1 and 2 contain a 6-4 photo-adduct in an internally labeled substrate. CHO cellfree extracts were added to Lane 1 and a mock incision reaction was added to Lane 2.
Lane 3 contains an end-labeled New30 and Lane 4 contains end-labeled N ew l3 as size
markers.
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Figure 3. In vitro binding affinity of New TFOs. TFOs o f different lengths were
bound to a 57 bp end-labeled duplex and binding affinity was determined by the
dissociation constant (Kd) which is the concentration o f TFO where half of the duplex is
bound to TFO and half is unbound, under the given set o f conditions (10 mM Tris, pH
7.6, 10 mM M gCh, 1 mM spermine). The bands o f reduced mobility relative to the
duplex alone represent triplex formation.
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Figure 4. Mono-adduct versus cross-link formation with New TFOs. Using the same
57 bp duplex used in Fig. 3, the time o f UVA exposure required to maximize monoadduct formation was determined using psoNewlO. Lanes 1, 3, 5, 7, and 9 represent
duplex alone without psoNewlO. Lanes 2, 4, 6 , 8 , and 10 represent duplex with
psoNewlO bound as described in Fig. 3. Lanes 1 and 2 were treated with UVA at 320 nm
for 10 seconds. Lanes 3 and 4 were treated for 30 seconds. Lanes 5 and 6 were treated
for 1 minute. Lanes 7 and 8 were treated for 3 minutes. Lanes 9 and 10 were treated for
6 minutes.
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Figure 5. Incision of linear substrate adducted to a 3'-end-labeled TFO. Lanes 1 and
2 show 10 pM and 100 uM of psoNew24 alone. Lane 3 shows NEWAG and psoNew24,
bound, mono-adducted, and incubated with CHO cell-free extracts. The arrow indicates
excision products. Lane 4 shows the same binding, mono-adduction, and incubation in
the same buffers as Lane 3, but no cell-free extracts were added. Lanes 5, 6 , 7, 8 , and 9
show end-labeled N ew l 1, N ew l5, New20, New24, and New30, respectively.
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Figure 6. Purification of incision substrate. (A) A substrate containing the triplex
binding of NEWAG (a 195 bp linear substrate) and psoNew24 followed by mono-adduct
formation. (B) The substrate after disruption o f triplex binding and size filtration to
remove excess, unbound TFO. (C) Gel purification o f the substrate.
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Figure 7. Incision of a substrate after size filtration. Lanes 1 and 2 show the flow
through as purification by size filtration proceeded. Lanes 3 and 4 show psoNew24
mono-adducted to NEWTC. CHO cell-free extracts were added to Lane 3 and a mock
reaction was added to Lane 4. Lanes 5 and 6 show psoNew24 mono-adducted to
NEWAG. CHO cell-free extracts were added to Lane 5 and a mock reaction was added
to Lane 6 . Lane 7 shows psoNew24 alone. Arrows indicate possible incision products
and asterisks indicate substrate (NEWAG or NEW TC with psoNew24). Lanes 8-11
show end-labeled New30, New24, New20, and N ew l5, respectively.
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Figure 8. Incision of a purified, linear substrate adducted to psoralen TFOs. Lane 1
shows NEWAG and psoNew l5, bound, mono-adducted, and incubated with cell-free
extracts. Lane 2 had the same substrate but was mock incubated without extracts. Lane 3
shows NEWAG and psoNew24, bound, mono-adducted, and incubated with cell-free
extracts. Lane 4 had the same substrate but was mock incubated without extracts. Lanes
5 and 6 show substrates NEWAG with psoNew l5 and NEW AG with psoNew24 without
extract incubation or mock incubation, respectively. Arrows indicate possible incision
products and asterisks indicate substrate (NEWAG with psoNew l5 or with psoNew24).
Lanes 7-10 showed end-labeled N ew l5, New20, New24, and New30, respectively.
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Figure 9. Construction of an internally labeled duplex. Lane 1 shows a 195 bp
double stranded fragment. Lane 2 shows a ligation with IC2 labeled, fragment sizes
within this lane include 137 bp, 85 bp, and 33 bp. Lane 3 shows a ligation with IC3
labeled, fragment sizes including 137 bp, 85 bp, and 52 bp are seen. Lane 4 shows a
ligation with IC 6 labeled, fragment sizes o f 137 bp, 94 bp, and 44 bp are seen. Lane 5
shows the 52 bp fragment (IC3) and Lane 6 shows the 44 bp fragment (IC 6 ) alone. 137
bp is the size o f the fully ligated product (see arrow).
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Gene targeting via homologous recombination (HR) offers a potential strategy for
therapeutic correction of mutations in disease-related human genes. However, there is a
need to improve the efficiency o f site-specific recombination by transfected DNAs.
Oligonucleotide-mediated triple helix formation has been shown to constitute a DNA
lesion sufficient to provoke DNA repair and thereby stimulate recombination. Triplexforming oligonucleotides (TFOs) bind to duplex DNA in a sequence-specific manner and
are potential tools to achieve targeted gene modification. Initial studies demonstrated the
ability of TFOs to deliver mutagenic agents in a DNA site-specific manner. Gene
modification with TFOs includes induced recombination between a DNA target and a
donor DNA molecule, a process that allows a TFO to exert an effect at a distance from
the third-strand binding site. It was also found that TFOs in the purine m otif can induce
gene modification in chromosomal DNA via the effect of the triple helix itself but thus
far, the effect o f the pyrimidine m otif TFO alone has not been demonstrated.
The work presented here expands the number of possible target sites for TFOinduced gene correction by demonstrating the effect o f pyrimidine TFOs, independent of
a DNA reactive conjugate, to induce recombination and repair. However, the ability of
triplex-forming oligonucleotides to induce recombination between a target locus and a
donor DNA was so far previously demonstrated only with multi-copy episomal targets in
mammalian cells. This work demonstrates the activity of purine and pyrimidine m otif
TFOs in a single-copy chromosomal target. Previous work in the Glazer lab
demonstrated that triplex-induced mutagenesis and recombination is dependent on the
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nucleotide excision repair (NER) pathway [1-4]. The mechanism o f incision o f a triplex
during repair is not currently understood and these experiments are designed to illuminate
aspects o f this mechanism.
We established that a number o f chemically modified TFOs in the pyrimidine
motif showed enhanced binding affinity. These included N3'->P5' phosphoramidate
(amidate), 5-(l-propynyl)-2'-deoxyuridine (pdU), 2 - 0 , 4'-C-methylene bridged or
locked nucleic acid (LNA), 2'-0-methyl-ribose (2'-0-M e), and 2'-0-(2-aminoethyl)ribose (2'-AE)-modified TFOs. Other chemical modifications such as N, Ndiethylethylenediamine (DEED), 5-methyl-2'-deoxycytidines (5meC), and morpholino
(morph) which we expected to show enhanced binding affinity based on previous use of
these modifications for antisense and other gene modification technology did not show
such affinity.
Enhanced binding affinity was necessary but not sufficient to induce
recombination in cells and repair in cell-free extracts as only the amidate and pdUmodified TFOs showed such activity. The amidate TFO showed similar induction of
recombination to that demonstrated previously with the purine m otif TFO, AG30, in an
analogous reporter system. The amidate-induced recombination, like the AG30-induced
recombination, was shown to be dependent on XPA. The amidate effect was not based
on enhanced nuclease stability compared to the other chemically modified TFOs tested.
These results show that amidate and pdU-modified TFOs can be used as reagents to
stimulate site-specific gene targeting without the need for conjugation to DNA-reactive
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molecules. The biological activity o f the more DNA-like TFOs (amidate and pdU)
demonstrated here and the lack of activity o f the more RNA-like TFOs (LNA, 2'-0-M e,
2'-AE) in conjunction with NMR data by Asensio et ah, which showed that triplexes with
a DNA third strand are more helically distorting than those with a RNA third strand [5],
suggests that greater helical distortion favors greater recognition by DNA repair
mechanisms and therefore greater induction o f recombination.
The efforts to test a series o f chemical modifications on the third strand presented
here led to the identification of the amidate modification as an inducer o f recombination
and repair based on the effect o f the TFO alone. Demonstrating for the first time that an
unconjugated TFO in the pyrimidine m otif is biologically active and thereby, increasing
the number o f target sites possible for gene correction. These efforts provide a
standardized screening method for testing novel chemical modifications as they are
developed. Since the initial publication o f the amidate work, we screened several new
modifications but found that the amidate was still the most effective modification tested.
The biological activity o f the amidate demonstrated above was in an episomal
target in cells or in cell-free extracts. In order to demonstrate gene correction with TFOs
as a model for gene therapy, a single-copy chromosomal target was designed using the
firefly luciferase reporter gene. CHO cell lines containing triplex binding sites upstream
of &firefly luciferase gene containing a stop codon, were made with purine and
pyrimidine binding sites, respectively. The cell lines all had the same integration site for
the TBS and reporter gene and cell lines with the wild-type luciferase gene were also
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made. The sensitivity o f the assay was determined to be less than 0.01%, where one
wild-type cell could be detected among 10,000 mutant cells. Gene correction was
achieved when TFOs were contransfected with single-stranded DNA donors at
frequencies up to 0.1%. The TFO-induced correction was target site, sequence, and dose
dependent.
The pyrimidine TFO, am idatel8, and the purine TFO, AG30, showed similar
levels o f gene correction, demonstrating that correction was independent o f the
orientation of the TFO. Antisense DNA donors (homologous to the transcribed strand o f
the duplex) were more effective in inducing recombination in conjuction with TFO
binding than sense donors. The 51-mer donor, end-modified with phosphorothioate
linkages was most effective compared to a 30-mer and 69-mer donor and to LNAmodified donors. In comparison to other chemically modified TFOs in the pyrimidine
motif, the amidate modified-TFO showed the highest percentage o f induced
recombination. In total, this work demonstrated the effectiveness o f TFOs in targeting a
single-copy chromosomal target and suggests the usefulness o f TFOs as sequencespecific gene modification tools.
Finally, we developed an assay to detect incisions made in repair of a triplex. We
demonstrated the excision activity o f cell-free extracts and designed a triplex substrate to
detect incisions. This substrate consisted of a 195 bp duplex and a TFO with a 5'psoralen and a 3'-radiolabel. The TFO was bound to the duplex, mono-adducted, size
filtered, and gel purified. The purified substrate was incubated with cell-free extracts or
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mock-incubated without extracts. Using a 15-mer and a 24-mer TFO, incision products
were detected in repair o f a triplex. These products were smaller than the initial substrate
and similar for both the 15-mer and the 24-mer TFO bound substrates. Smaller excision
fragments were not detected. This work represents first steps towards understanding the
nature o f incisions made in repair o f a triplex structure. Future work will further
investigate the nature o f the incisions detected here. Placing the radiolabel at different
locations along the duplex DNA will allow for a more precise location o f where the
incisions were made.
Future directions o f TFO technological development include the identification of
novel chemical modifications to further enhance the biological activity o f TFOs and the
development o f new techniques for TFO delivery to enhance the biological effectiveness
of these reagents. Additionally, further steps towards identifying the mechanism o f repair
o f a triplex such as the exact nature o f the incisions and the nature o f involvement of
repair pathways besides NER need to be made. The interplay between the different
repair pathways at work in repair o f a triplex lesion is not understood and future
directions of this work lie in deciphering these interactions.
In summary, our work suggests that high-affmity DNA binding ligands, such as
TFOs, can be used to mediate site-specific genome modification. This capacity derives
not only from the ability o f TFOs to bind as third strands with sequence specificity but
also from the ability o f the resulting triple helices to provoke repair, leading to directed
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mutagenesis, recombination, and potentially gene correction.
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